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ABSTRACT
TOPICS IN STATISTICAL INFERENCE FOR TREATMENT EFFECTS
Yang Jiang
Dylan Small
Nancy Zhang
This thesis unites three papers discussing different approaches for estimating treatment
effects, either in observational study or randomized trial. The first paper presents an ap-
proach to sensitivity analysis for the instrumental variable(IV) method, which examines the
sensitivity of inferences to violations of IV validity. Our approach is based on extending
the Anderson-Rubin test and is robust to weak IVs. The second paper presents a unified R
software ivmodel for analyzing instrumental variables with one endogenous variable. The
package implements a general class of estimators, k-class estimators, and two confidence
intervals that are fully robust to weak instruments. The package also provides power for-
mulas. The sensitivity analysis discussed in the first paper is also included in the package.
The third paper uses Hidden Markov Model to estimate the dynamic effects of lottery-
based incentives towards patient’s healthy behavior every day. The data is collected from
randomized clinical trials.
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CHAPTER 1 : Introduction
This thesis is based on three papers, all of which address estimating treatment effects via dif-
ferent approaches. The first paper discusses the usage of current instrumental variable(IV)
method in a less restricted scenario. In observational studies to estimate treatment effects,
unmeasured confounding is often a concern. The IV method can control for unmeasured
confounding when there is a valid IV. To be a valid IV, a variable needs to be independent
of unmeasured confounders and only affect the outcome through affecting the treatment.
When applying the IV method, there is often concern that a putative IV is invalid to some
degree. We present an approach to sensitivity analysis for the IV method, which examines
the sensitivity of inferences to violations of IV validity. Our approach is based on extending
the Anderson-Rubin test and is robust to weak IVs. A power formula for this sensitivity
analysis is presented. We illustrate its usage via examples about Mendelian randomization
studies and its implications via a comparison of using rare vs. common genetic variants as
instruments.
The second paper presents a unified R software ivmodel for analyzing instrumental variables
with one endogenous variable. The package implements a general class of estimators, k-
class estimators, and two confidence intervals that are fully robust to weak instruments. The
package also provides power formulas. Finally, the package contains methods for sensitivity
analysis to examine the sensitivity to the the instrumental variables assumptions. We
demonstrate the software on the data set from Card (1995), looking at the causal effect
of levels of education on log earnings where the instrument is the proximity to a four-year
college. The approach developed in the first paper is also programmed in the package.
The third paper studies a treatment effects in randomized trials. Poor adherence to medical
treatments can have large impact on health outcomes and health care costs. However,
adherence is difficult to maintain, especially for long-term medication. Financial incentives
are increasingly used as a method to improve medication adherence. Current literature
1
analyzes the overall effect of incentives applied to treatment group comparing to control
group. In this paper, we focus on analyzing the dynamic effects of lottery-based incentives
towards patient’s healthy behavior every day. Hidden Markov Model is used in the modeling
part and EM-algorithm and bootstrap methods are used for point estimation and confidence
interval. The data is collected from 3 different clinical trials.
2
CHAPTER 2 : Sensitivity Analysis and Power for
Instrumental Variable Studies
2.1 Introduction
In observational studies, it is challenging to make causal inference about treatment effects
due to the potential presence of unmeasured confounding or reverse causation. One ap-
proach to address these challenges is the instrumental variable (IV) method, which uses an
instrument to extract a quasi-random experimental study from an observational study. The
method requires a valid IV, which is a variable that satisfies three conditions: (IV-C1) the
IV is associated with the exposure; (IV-C2) there are no unmeasured confounders between
the IV and outcome; (IV-C3) the IV affects the outcome only through its effect on the ex-
posure. See Angrist et al. (1996a), Herna´n and Robins (2006), Brookhart and Schneeweiss
(2007), Baiocchi et al. (2014a) and Imbens (2014) for more discussions of IV.
unmeasured 
confounders
IV exposure outcome
(3)
(2)
(1)
Figure 1: A valid IV requires three conditions. The dash-dotted line suggests that the IV is
associated with the exposure, which is IV-C1. The non-existing (“X” symbol in the figure
means non-existing) dotted line suggests that the assignment of IV is independent of the
unmeasured confounders, which is IV-C2. Similarly, the non-existing dashed line represents
IV-C3 that the IV affects the outcome only through its effect on the exposure.
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Figure 1 depicts three conditions for a variable being a valid IV and the relationship between
the IV, exposure, outcome and unmeasured confounders. When applying the IV method in
a real study, investigators need to evaluate if there are any variables which satisfy the three
conditions for being a valid IV. While (IV-C1) can be tested from the observed data, (IV-
C2) and (IV-C3) cannot be completely tested, see Morgan and Winship (2007a). Therefore,
it is often difficult to know whether an IV is perfectly valid in a study. Even when an IV is
invalid, it may still be useful if the inferences from using the IV are not sensitive to plausible
magnitudes of invalidity, which can be assessed through a sensitivity analysis (Angrist
et al., 1996a; Imbens and Rosenbaum, 2005; Brookhart and Schneeweiss, 2007; Small and
Rosenbaum, 2008). There is some previous work on sensitivity analysis for IV studies, see
DiPrete and Gangl (2004a), Small (2007a), Kolesa´r et al. (2011a) and Conley et al. (2012a).
These papers all use test statistics which are based on the two stage least squares estimator
having an approximately normal distribution, which breaks down in the presence of weak
instruments (instruments that are weakly associated with the exposure), see Nelson and
Startz (1990a). This weak IV issue is very common in Mendelian randomization studies
(Lawlor et al. (2008a), Section 4.10), in which genetic variants are used as IVs. See Section
2.5 for discussion of Mendelian randomization studies.
For settings with one IV that is either weak or strong, the Anderson-Rubin (AR) test
(Anderson and Rubin, 1949a) has been shown to have good properties. Under the normal
linear structural equation model setting that is reviewed in Section 2.2, the AR test is
an exact test regardless of the strength of the IV. When the covariance matrix of the
structural errors is known, Moreira (2001a) proved that AR test is uniformly most powerful
among all unbiased tests; Andrews et al. (2006a) also proved that the AR test is uniformly
most powerful among all invariant similar tests. When the covariance matrix is unknown,
Andrews et al. (2006a) showed that AR test is asymptotically efficient for local alternatives
under some regularity conditions.
Since the AR test has good performance for both weak and strong IVs, in this paper,
4
we develop a method of sensitivity analysis for instrumental variables based on the AR
test. We demonstrate that the sensitivity analysis is robust to weak instruments unlike
previous sensitivity analyses. Another contribution we make is that we give a power formula
for the sensitivity analysis. The power formula enables researchers to decide how large a
sample to collect if the goal is to find evidence for an exposure effect that is insensitive
to a specified amount of invalidity of the IV. We show that when considering sensitivity
analysis, the concentration parameter(F statistic), which is a commonly used criterion for
measuring IV strength, is no longer a good measure for achieving a large power. Instead,
it is better to focus on the IV effect size. This has important implications for the design of
Mendelian randomization studies, in particular the choice between focusing on common vs.
rare variants, which will be discussed in Section 2.5.
The remainder of this paper is organized as follows: In Section 2.2, we formulate a potential
outcome model with a possibly invalid IV. In Section 2.3, we review the original 2SLS
estimator and the AR test. In Section 2.4, we present our sensitivity analysis approach
and provide the power formula for sensitivity analysis. In Section 2.5 we show how to do
sensitivity analysis and calculate power in applications, including Mendelian randomization
studies with common vs. rare variants. Section 2.6 provides conclusions.
2.2 Instrumental Variable Model with Possible Invalid In-
struments
In this section, following Holland (1988a), we formulate a causal potential outcomes model
(Rubin, 1974a; Splawa-Neyman et al., 1990) with a possibly invalid IV and connect it to
the simultaneous equations model Hausman (1983). By doing so we can precisely define
unit-level causal effects, obtain causal interpretations of certain regression coefficients and
model possible violations of IV validity.
This paper will consider the setting of one IV and one exposure. For individual i, we use
Zi, Di, Yi to represent the observed IV, exposure and outcome accordingly. We use Y
(d,z)
i
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to denote the potential outcome under the scenario where the individual i is assigned the
exposure d and IV z. The variable Y
(d,z)
i is the potential outcome individual i would have if
we forcefully assign her/him to have exposure d and IV z. Similarly, D
(z)
i is defined as the
“potential exposure”, which is the exposure individual i would have if we forcefully assign
her/him to IV z. Notice that D(z)|(Z = z) might not equal D(z)|(Z = z′) because even
though we are comparing what would happen if two sets of subjects (those with Z = z vs.
those with Z = z′ got forcefully assigned the same level z of the IV, the set of subjects with
observed Z = z might have different levels of confounders than the set of subjects with
observed Z = z′.
The first assumption we make is that the observed subjects i = 1, . . . , n are an i.i.d. sample
from a population. We also assume the effect of the IV on the exposure is linearly additive,
i.e., for each extra unit of IV forcefully assigned, the potential exposure will increase by η
units for every individual:
D
(z)
i −D(0)i = ηz, ∀i (2.1)
in other words, η is the unit-level causal effect of the IV on exposure. For the potential
exposure D
(0)
i , we can write it as:
D
(0)
i = E(D
(0)
i |Zi = 0) + (E(D(0)i |Zi)− E(D(0)i |Zi = 0)) + (D(0)i − E(D(0)i |Zi))
= E(D(0)i |Zi = 0) + κ(Zi) + vi, ∀i (2.2)
where E(D(0)i |Zi = 0) is the population average of the potential exposure D(0) given that
Z = 0. The variations in {D(0)i ; i = 1, . . . , n} among different individuals come from two
sources: 1) κ(Zi) = E(D
(0)
i |Zi) − E(D(0)i |Zi = 0) measures the effect of unmeasured con-
founders between the IV and exposure. Different values of Zi are associated with different
levels of unmeasured confounders, which result in a difference of κ(Zi). Notice that κ(0) = 0,
if κ(Z) = 0 for all possible values of Z, then there are no unmeasured confounders between
the IV and exposure. We further assume this confounding effect is linear, so κ(Z) = κZ.
2) The error term vi = D
(0)
i − E(D(0)i |Zi) can be understood as the individual error of the
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potential exposure after removing the effect of all unmeasured confounders between the IV
and exposure. vi has a mean 0, E(vi) = E(D
(0)
i ) − E(E(D(0)i |Zi)) = 0. We further assume
vi and Zi are independent. Combining (2.1) and (2.2) and writing E(D
(0)
i |Zi = 0) = γ0, we
get the following “first stage” model that relates the observed D to the observed Z:
Di = D
(Zi)
i =
(
D
(Zi)
i −D(0)i
)
+ E(D(0)i |Zi = 0) + κ(Zi) + vi
= γ0 + ηZi + κZi + vi
∀i, vi is i.i.d. with mean 0; vi ⊥ Zi (2.3)
Z D Y
unmeasured
confounders v u
𝜅(⋅) 𝛿1(⋅)
𝛿2(⋅)
𝜂 𝛽
Figure 2: Complete DAG for the model in Section 2.2. The dashed arrows represent the
first stage model and the solid arrows represent the second stage model.
(this is called the first stage model because it is the first stage in two stage least squares)
The dashed arrows in Figure 7 show the causal relationship for our first stage model.
Now we consider the second stage model that relates the observed Y to the observed D.
Assume that the causal effect for the exposure on the potential outcome is linear and it has
no interaction with the IV, i.e., for each extra unit of exposure that is forcefully assigned,
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the potential outcome will increase by β units for every individual:
Y
(d,z)
i − Y (0,z)i = βd, ∀i (2.4)
in other words, β is the unit-level causal effect of the exposure on outcome. Define δi1(·) as:
δi1(z) = Y
(0,z)
i − Y (0,0)i , ∀i (2.5)
Combining (2.4) and (2.5), we have:
Y
(d,z)
i − Y (d,0)i = (Y (0,z)i + βd)− (Y (0,0)i + βd) = δi1(z), ∀i (2.6)
Equation (2.6) says δi1(·) measures how much the IV affects the outcome through paths
other than through the exposure for individual i. We assume this effect is linear and has no
variation among different individuals, therefore δi1(Z) = δ1Z. If δ1 ≡ 0, then Y (d,z)i ≡ Y (d,0)i ,
meaning that the IV affects the outcome only through its effect on the exposure, which is
condition (IV-C3) for being a valid IV.
For the potential outcome term Y
(0,0)
i , we can write it as:
Y
(0,0)
i = E(Y
(0,0)
i |Zi = 0) + (E(Y (0,0)i |Zi)− E(Y (0,0)i |Zi = 0)) + (Y (0,0)i − E(Y (0,0)i |Zi))
= E(Y (0,0)i |Zi = 0) + δ2(Zi) + ui, ∀i (2.7)
where E(Y (0,0)i |Zi = 0) is the population average of the potential outcome Y (0,0) given
that Z = 0. The variations in {Y (0,0)i ; i = 1, . . . , n} come from two sources: 1) δ2(Zi) =
E(Y (0,0)i |Zi)−E(Y (0,0)i |Zi = 0) measures the effect of unmeasured confounders between the
IV and outcome. Different values of Zi are associated with different levels of unmeasured
confounders, which result in a difference of δ2(Zi). Notice that δ2(0) = 0. If δ2(Z) = 0
for all possible values of Z, then there are no unmeasured confounders between the IV
and outcome, which is condition (IV-C2) for being a valid IV. We further assume this
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confounding effect is linear, so δ2(Z) = δ2Z. 2) The error term ui = Y
(0,0)
i − E(Y (0,0)i |Zi)
can be understood as the individual error of the potential outcome after removing the effect
of all unmeasured confounders between the IV and outcome. ui has a mean 0, E(ui) =
E(Y (0,0)i ) − E(E(Y (0,0)i |Zi)) = 0. We further assume ui and Zi are independent. Notice
that although ui is independent of the unmeasured confounders between the IV and the
outcome, ui may still be associated with the unmeasured confounder between the exposure
and outcome, so ui is not independent of Di or vi. Combining (2.4)-(2.7) and writing
E(Y (0,0)i |Zi = 0) = β0, we get the “second stage” model that relates the observed Y to the
observed Z:
Yi = Y
(Di,Zi)
i
=
(
Y
(Di,Zi)
i − Y (0,Zi)i
)
+
(
Y
(0,Zi)
i − Y (0,0)i
)
+
(
E(Y (0,0)i |Zi = 0) + δ2(Zi) + ui
)
= β0 + βDi + δ1Zi + δ2Zi + ui
∀i, ui is i.i.d. with mean 0, ui ⊥ Zi (2.8)
The solid arrows in figure 7 show the causal relationship for our second stage model. Com-
bining (2.3) and (2.8) and assuming vi and ui are bivariate normal our complete model can
be written as:
Yi = β0 + βDi + (δ1 + δ2)Zi + ui
Di = γ0 + (η + κ)Zi + vi
(ui, vi) ⊥ Zi; (ui, vi)T ∼ N (0,Σ) ; Σ =
 σ21 ρσ1σ2
ρσ1σ2 σ
2
2
 (2.9)
Here the parameter of interest is β, which represents the unit-level causal effect of the
exposure on the outcome. δ1 measures the violation of condition (IV-C3) for being a valid
IV. δ2 measures the violation of condition (IV-C2) for being a valid IV. The model (2.9)
has the same structure as the models for sensitivity analysis in DiPrete and Gangl (2004a),
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Kolesa´r et al. (2011a) and Conley et al. (2012a). As a summary, (2.9) relies on the following
assumptions: 1) the observed subjects are an i.i.d. sample from a population; 2) the causal
effects of the IV on the exposure and the exposure on the outcome are linearly additive; 3)
the confounder function κ(·) and the IV violation functions δi1(·), δ2(·) are linear and δi1(·)
is homogeneous for all individual i; 4) the error terms (ui, vi) are bivariate normal and
independent of Zi.
We can reduce the number of parameters in (2.9) by defining γ = η + κ, δ = δ1 + δ2. Here
γ is the coefficient of IV Z in the first stage model. Z will satisfy condition (IV-C1) as
long as γ 6= 0, i.e., the IV only needs to be associated with the exposure and could have no
causal effect on the exposure (η = 0) (Herna´n and Robins, 2006). The parameter δ1 and δ2
measures the violation of valid IV conditions and combined into δ = δ1 + δ2, so that δ can
be treated as the sensitivity parameter in (2.9), which describes the amount of invalidity of
the IV.
There are other observed covariates (write as vector Xi of length k) for each individual i,
they can be added into (2.9) as:
Yi = β0 + β
T
XXi + βDi + δZi + ui
Di = γ0 + γ
T
XXi + γZi + vi
Writing the vector form of the observations as Yn×1 = (Y1, . . . , Yn)T , Dn×1 = (D1, . . . , Dn)T ,
Xn×k = (X1, . . . , Xn)T etc, and also merging the intercept into the observed covariates X,
we get an analogous model to (2.9):
Y = XβX + βD + δZ + u
D = XγX + γZ + v
(u, v) ⊥ Z; (ui, vi)T ∼ N (0,Σ) ; Σ =
 σ21 ρσ1σ2
ρσ1σ2 σ
2
2
 ; rank(X) = k
(2.10)
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Since βX and γX are not of interest, we can use the Frisch-Waugh-Lovell theorem (Davidson
and MacKinnon, 1993a; Wang and Zivot, 1998) to transform the model (2.10) by using the
projection matrix MX = IN×N −X(XTX)−1XT . Also, to make the sensitivity parameter
δ in the model more interpretable, we rescale δ as δσ1. After this rescaling, a unit change
in the invalid IV Z will lead to a change of δ standard deviations of the structural error
u = Y (0,0) − E(Y (0,0)|Z). The final model after transforming and rescaling becomes:
Y ∗ = βD∗ + δσ1Z∗ + u∗
D∗ = γZ∗ + v∗
Y ∗ = MXY ; D∗ = MXD; Z∗ = MXZ; u∗ = MXu; v∗ = MXv;
(u, v) ⊥ Z; (ui, vi)T ∼ N (0,Σ) ; Σ =
 σ21 ρσ1σ2
ρσ1σ2 σ
2
2
 rank(X) = k
(2.11)
(A.1) is the model we will consider in the rest of the paper. In the following sections, our
work will mainly focus on inference for β, given restrictions on the range of the sensitivity
parameter δ.
2.3 The 2SLS method and the Anderson-Rubin test
In this section, we consider model (A.1) with δ = 0, which is the usual two stage IV
regression model with a valid IV. We will briefly review the two stage least squares estima-
tor(2SLS) that has an asymptotic normal distribution and the standard AR test.
The 2SLS estimator of β is found by first regressing D∗ on Z∗ to find Dˆ∗, and then regressing
Y ∗ on Dˆ∗. The 2SLS estimator can be writen as follows:
βˆ2SLS =
cov(Z∗, Y ∗)
cov(Z∗, D∗)
=
Z∗TY ∗
Z∗TD∗
(2.12)
As the sample size increases to infinity, βˆ2SLS → β. Also the asymptotic variance for βˆ2SLS
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(Nelson and Startz, 1990a) is:
Asymptotic Variance(
√
n× (βˆ2SLS − β)) = σ
2
u∗ · V ar(Z∗)
Cov2(Z∗, D∗)
(2.13)
(2.12) and (2.13) can be used to construct an asymptotically valid t-test. However, when the
IV is weak, the asymptotics of this test may provide a poor guide to the actual performance
of the test even for moderately large sample sizes. (Nelson and Startz, 1990a; Staiger and
Stock, 1997a)
From Anderson and Rubin (1949a), the AR test compares the null and alternative hypothe-
ses:
H0 : β = β0 vs. H1 : β 6= β0
If the IV is valid, then under H0, Y
∗ − β0D∗ = u∗ is independent of Z∗. The coefficient of
regressing Y ∗ − β0D∗ = u∗ on Z∗ should be 0. The AR test is an F test for this coefficient
being 0. It has the following expression:
AR(β0) =
(Y ∗ − β0D∗)TPZ∗(Y ∗ − β0D∗)
(Y ∗ − β0D∗)TMZ∗(Y ∗ − β0D∗)/(n− k − 1) (2.14)
where n is the number of samples, PZ∗ , MZ∗ are projection matrices PZ∗ = Z
∗(Z∗TZ∗)−1Z∗T
and MZ∗ = In−PZ∗ . Under H0 : β = β0, since u∗TPZ∗u∗ ∼ σ21χ21, u∗TMZ∗u∗/(n−k−1) ∼
σ21χ
2
n−k−1 and they are independent (see more details in the Supplementary Materials), we
have:
AR(β0) =
u∗TPZ∗u∗
u∗TMZ∗u∗/(n− k − 1)
∼ F1,n−k−1 (2.15)
We rejectH0 whenAR(β0) > F1,n−k−1;1−α, where α is the significance level and F1,n−k−1;1−α
is the 1 − α quantile of F distribution with degree of freedom 1 and n − k − 1. (Notice
that since u∗ is the error after projecting out the effect of the covariates which include an
intercept, there are only n− k− 1 degree of freedom in the denominator.) In contrast with
the t-test based on the 2SLS estimator, the Anderson-Rubin test has correct size regardless
of the sample size and strength of the IV.
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We can construct a 1−α confidence interval (CI) from the AR test by solving the inequality:
CI1−α = {β : (Y
∗ − βD∗)TPZ∗(Y ∗ − βD∗)
(Y ∗ − βD∗)TMZ∗(Y ∗ − βD∗)/(n− k − 1) ≤ F1,n−k−1;1−α} (2.16)
We calculate the power functions for the AR test in the Supplementary Materials. Under
the alternative hypothesis H1 : β − β0 = λ, the power formula is:
Power = Pλ(AR(β0) > F1,n−k−1;1−α) = 1−Ψ
1,n−k−1, γ2Z∗T Z∗
σ22
Λ
(F1,n−k−1;1−α) (2.17)
where Λ = λ
2
(σ1/σ2)2+2ρσ1/σ2λ+λ2
, Ψa,b,k(·) is the CDF of the non-central F-distribution with
degree of freedom a, b and non-centrality parameter k. The term γ2Z∗TZ∗/σ22 is called the
concentration parameter, the larger the concentration parameter is, the larger the power
is. The concentration parameter is the population value of the first stage F statistic for
the IV when the treatment is regressed on it. It is used as a popular measure for instru-
ment strength (Stock et al., 2002a). Large values of the concentration parameter indicate
strong instruments. See Rothenberg (1984), Section 6.1 for more information about the
concentration parameter.
Before closing this section, we want to point out that the strength of the IV poses a funda-
mental limit on the power in IV studies. Looking at equation (2.17), if the concentration
parameter is fixed, then no matter how large the effect size λ/σ1 is, Λ has a fixed upper
bound 1/(1− ρ2) and the power has an upper bound:
1−Ψ
1,n−k−1, γ2Z∗T Z∗
σ22(1−ρ2)
(F1,n−k−1;1−α)
Therefore the power will not increase to 1 as the effect size increases to infinity. Thus, the
concentration parameter imposes a fundamental limit on the power of the AR test which
cannot be overcome with a large effect size of the treatment.
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2.4 Sensitivity Analysis and Power of Sensitivity Analysis
For our sensitivity analysis, we assume that δ ∈ (δ, δ¯) in model (A.1) and consider what
inference we can make if we do not know the value of δ but know its range (δ, δ¯).
2.4.1 CI and power formula for sensitivity analysis using AR test
First suppose we know the true value of the sensitivity parameter δ in Y ∗ = βD∗+δσ1Z∗+
u∗. The AR test statistic under H0 : β = β0 becomes:
AR(β0) =
(Y ∗ − β0D∗)TPZ∗(Y ∗ − β0D∗)
(Y ∗ − β0D∗)TMZ∗(Y ∗ − β0D∗)/(n− k − 1)
=
(
δσ1
√
Z∗TZ∗ + Z
∗Tu∗√
Z∗TZ∗
)2
u∗TMZ∗u∗/(n− k − 1)
∼ F1,n−k−1,δ2Z∗TZ∗ (2.18)
where Fa,b,c stands for the non-central F distribution with degree of freedom a, b and non-
central parameter c. Therefore a 1− α CI can be obtained as:
CI1−α(δ) = {β : (Y
∗ − βD∗)TPZ∗(Y ∗ − βD∗)
(Y ∗ − βD∗)TMZ∗(Y ∗ − βD∗)/(n− k − 1) < F1,n−k−1,δ2Z∗TZ∗;1−α}
(2.19)
where Fa,b,c;1−α stands for the 1−α quantile of the distribution Fa,b,c defined as above. Now
let’s go back to the assumption where we only know δ ∈ (δ, δ¯). Define ∆ = max(|δ|, |δ¯|).
We can construct a CI for β which will provide at least 1−α coverage by taking the union
of CI1−α(δ), for every δ ∈ (δ, δ¯):
CI1−α = ∪δ∈(δ,δ¯) CI1−α(δ)
= {β : (Y
∗ − βD∗)TPZ∗(Y ∗ − βD∗)
(Y ∗ − βD∗)TMZ∗(Y ∗ − βD∗)/(n− k − 1) < F1,n−k−1,∆2Z∗TZ∗;1−α} (2.20)
We now consider the power for being able to reject H0 : β = β0 for all δ ∈ (δ, δ¯) when the
true δ is δ∗. For calculating the power, details are derived in the Supplementary Materials
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and here we only show the main results. Under H1 : β − β0 = λ 6= 0, we have,
AR(β0) ∼ F
1,n−k−1, (γ+δ∗σ1/λ)2Z∗T Z∗
σ22
Λ
(2.21)
therefore,
Powerδ∗ = Pλ(AR(β0) 6∈ CI1−α)
= Pλ(AR(β0) > F1,n−k−1,∆2ZTZ;1−α)
= 1−Ψ
1,n−k−1, (γ+δ∗σ1/λ)2Z∗T Z∗
σ22
Λ
(
F1,n−k−1,∆2Z∗TZ∗;1−α
)
(2.22)
Equation (2.22) calculates the probability of correctly rejecting H0 for a fixed value δ
∗ of δ.
For calculating the power of a sensitivity analysis, Rosenbaum (2010a) Chapter 14.2 suggests
calculating the power for the “favorable situation” in which there is a treatment effect and
in fact there is no bias from unmeasured confounding (δ∗ = 0), but we do not know that
there is no unmeasured confounding and want to be able to reject the null hypothesis of
no treatment effect given a certain magnitude of unmeasured confounding, i.e., δ ∈ (δ, δ¯)
in our setting. To calculate the power of sensitivity analysis under this favorable situation,
we plug δ∗ = 0 into (2.22):
Power0 = 1−Ψ
1,n−k−1, γ2Z∗T Z∗
σ22
Λ
(
F1,n−k−1,∆2Z∗TZ∗;1−α
)
(2.23)
Another type of power of sensitivity analysis calculation is to find the minimum power for
rejecting the null hypothesis of no treatment effect under a sensitivity analysis that allows
for unmeasured confounding in the range δ ∈ (δ, δ¯). To calculate this minimum power, we
take minδ∈(δ,δ¯) on the right hand side of (2.22).
Power ≥ min
δ∈(δ,δ¯)
Powerδ = 1−Ψ
1,n−k−1,
minδ∈(δ,δ¯)(γ+δσ1/λ)2Z∗T Z∗
σ22
Λ
(
F1,n−k−1,∆2Z∗TZ∗;1−α
)
(2.24)
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We have written functions for the R package “ivpack”, available on CRAN, that calculate
the sensitivity analysis confidence interval (2.20) (function ARsensitivity.ci), the power of
sensitivity analysis using formula (A.14) or (2.24) (function ARsensitivity.power) and the
minimum sample size needed for reaching a certain power in a sensitivity analysis (function
ARsensitivity.size).
2.4.2 Effect of Different Parameters on Power of Sensitivity Analysis
We consider the effect of different parameters on the power of sensitivity analysis. Here we
will focus on analyzing the power formula (A.14) for the favorable situation.
The power formula (A.14) involves two different non-central F distributions with two non-
centrality parameters:
ncp1 =
γ2Z∗TZ∗
σ22
Λ; ncp2 = ∆
2Z∗TZ∗
To analyze the influence of different parameters in the power formula, we study how they
affect the size of ncp1 and ncp2. The Supplementary Materials proves the following prop-
erties:
Proposition 1. In the power formula (A.14), we have
(a) If ncp1 = ncp2, the power is always α.
(b) For fixed ncp2, power increases as ncp1 increases.
(c) For fixed ncp1, power decreases as ncp2 increases.
(d) If ncp1 > ncp2, the power is larger than α and will increase to 1 as the sample size
increases.
(e) If ncp1 < ncp2, the power is smaller than α and will decrease to 0 as the sample size
increases.
16
The ncp2 = ∆
2Z∗TZ∗ is approximately equal to n ·∆2 · SD(Z∗)2. ∆ is determined by the
allowance of sensitivity and n is the sample size. The ncp1 is affected many parameters:
ncp1 =
γ2Z∗TZ∗
σ22
Λ =
γ2
σ22
· Z∗TZ∗ · 1
( σ1σ2λ + ρ)
2 + 1− ρ2
In Section 2.3 we stated that a large concentration parameter γ2Z∗TZ∗/σ22 will lead to a
large power in AR test, assuming that the IV is valid. However, if we are doing sensitivity
analysis and considering the power formula (A.14), a large concentration parameter may be
produced by a small |γ|/σ2 and a large Z∗TZ∗ (or vice versa). This will result in both large
ncp1 and ncp2, for which the power of sensitivity analysis may not be large. On the other
hand, if the IV effect size |γ|/σ2 increases and the other parameters keep the same values,
then ncp1 increases and ncp2 stays the same, which leads to a larger power of sensitivity
analysis. This suggests that if we want to have a large power of sensitivity analysis, we
should focus on finding a large IV effect size |γ|/σ2. We will discuss the implications of this
for Mendelian randomization studies in Section 2.5.2.
For the effect size λ/σ1, no matter how it varies, ncp1 has an upper bound γ
2Z∗TZ∗/(σ22(1−
ρ2)) when λ/σ1 = −(σ2ρ)−1. Hence the power of sensitivity analysis cannot go to 1 as the
effect size increases to infinity. This is similar to the discussions at the end of Section 2.3,
which is about the power property in AR test.
If the effect size λ/σ1 is very small or the IV effect size |γ|/σ2 is very small, then we may
have
1
( σ1σ2λ + ρ)
2 + 1− ρ2 ·
γ2
σ22
< ∆2 (2.25)
This will result in ncp1 < ncp2. Under such a situation, the sensitivity analysis cannot have
power larger than α for any sample size.
For further illustration, we simulated a simple scenario and calculated the power of sensi-
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tivity analysis by varying different parameters. We consider the following base parameters:
σ21 = 1; σ
2
2 = 4; ρ = 0.5; γ = 0.5; λ = −1; SD(Z) = 1; n = 200 (2.26)
and we want to use the power formula (A.14) under different allowance of sensitivity param-
eter interval δ ∈ [−0.05, 0.05], [−0.08, 0.08], or [−0.1, 0.1]. We will allow one combination
of parameters to vary at a time, to see what’s the effect upon the power.
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Figure 3: Power of sensitivity analysis in simulated scenario where the base parameters are
σ21 = 1, σ
2
2 = 4, ρ = 0.5, γ = 0.5, λ = −1, sd(Z) = 1, n = 200. In each graph we vary one
combination of parameters to observe the change of power.
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Figure 3 shows the result. In the top left graph, ρ varies between (−1, 1) while other
parameters are fixed. We can see the power increases as ρ increases when the effect size
λ/σ1 is negative. If the effect size λ/σ1 is positive, then power increases if ρ decreases. In
the top right graph, SD(Z∗) varies between (0, 1) while other parameters are fixed. We can
see the power increases as SD(Z∗) increases. If the inequality (2.25) holds, then the power
is smaller than α and will decrease as SD(Z∗) increases. In the bottom left graph, λ varies
between (−2, 2) while other parameters are fixed. This corresponds to the effect size λ/σ1
varying between (−2, 2). In general we can see the power is large when the effect size is
substantial. However, the upper bound for the power is when λ/σ1 = −(ρσ2)−1 = −1. As
λ/σ1 moves below -1, the power even starts to drop a little bit. This again corresponds to
the previous discussion that no matter how large the effect size is, there’s an upper bound
for the power. In the bottom right graph, σ2 varies between (2, 6) while other parameters
are fixed. This corresponds to the IV effect size γ/σ2 varying between (0.083, 0.25). In
general we can see the power increases as the IV effect size increases.
2.4.3 Design sensitivity
The design sensitivity describes the asymptotic power of sensitivity analysis (Rosenbaum,
2004, 2010a). Here we calculate the design sensitivity in our sensitivity analysis model.
Suppose the sensitivity range that δ lies is centered at 0: δ ∈ (−∆,∆). For large ∆, the
power of sensitivity analysis using power (A.14) tends to 0 as the sample size increases. For
small ∆, the power tends to 1 as the sample size increases. The switch point is defined as
the design sensitivity ∆DS .
To calculate the design sensitivity, we can use the property (d) and (e) in Proposition 3,
which tells us that the switch point happens when ncp1 = ncp2, so we have:
∆DS =
√
λ2γ2
σ21 + 2ρσ1σ2λ+ λ
2σ22
(2.27)
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Notice that ∆DS has an upper bound for any λ:
∆DS =
√
γ2
(σ1/λ+ ρσ2)2 + σ22(1− ρ2)
≤ |γ|
σ2
√
1− ρ2
Thus, no matter how large the effect size is, the design sensitivity is limited by the IV effect
size |γ|/σ2. This also suggests that the IV effect size is a better measure of IV strength
than the concentration parameter when we are concerned that IV might not be perfectly
valid and we would like to do a sensitivity analysis.
2.5 Applications of Sensitivity Analysis and Power Calcula-
tion to Mendelian Randomization Studies
An important application area of the IV method is Mendelian randomization studies (Smith
and Ebrahim, 2003, 2004; Lawlor et al., 2008a; Ebrahim and Smith, 2008; Glymour et al.,
2012). The basic idea of Mendelian randomization is to use inherited genetic variants as IVs
to study the effect of an exposure on an outcome. By Mendel’s second law, the transmission
of genetic variants between generations is independent of possible confounders like environ-
ment and lifestyle factors. This makes it plausible that genetic variants satisfy the condition
(IV-C2) for being a valid IV. If a generic variant is independent of unmeasured confounders
and is also associated with the exposure and affects the outcome only through the exposure,
then it is a valid IV. However, there are several ways that genetic variants could violate
the conditions for being a valid IV, such as linkage disequilibrium, population stratification
or pleiotropy (Didelez and Sheehan (2007) Section 7 and Lawlor et al. (2008a) Section 4).
For example, if a genetic variant used as an IV is linked to another unmeasured genetic
variant on the same chromosome that affects the outcome, there is linkage disequilibrium
and the condition (IV-C2) is violated. Another way that a genetic variant could violate
(IV-C2) is through population stratification (subpopulations which exhibit systematic dif-
ferences in genotypes due to different ancestries) which is associated with both the IV and
the outcome. Besides possibly violating (IV-C2), a genetic variant could violate (IV-C3) by
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being pleiotropic in such a way that the genetic variant influences both the exposure and
the outcome through a pathway other than the exposure. Consequently, in most studies
using Mendelian randomization, there is some concerned about whether the proposed IVs
are valid (e.g. see Nitsch et al. (2006)). It is useful to do a sensitivity analysis to examine
how sensitive the analysis results are to the violation of (IV-C2) and (IV-C3).
2.5.1 Applications to a Mendelian Randomization Study
Here we will use the same example in Freeman et al. (2013a) to illustrate how to do sensi-
tivity analysis and power calculation in a Mendelian randomization study.
The example concerns the causal effect of C-reactive protein (CRP), a marker of inflam-
mation, on fibrinogen, a maker for coronary heart disease. The gene that makes CRP has
several variations in the form of single nucleotide polymorphisms (SNPs). SNPs of the CRP
gene have commonly been used to study the causal effects of CRP in Mendelian random-
ization studies, e.g. see Lawlor et al. (2008a). Although the CRP gene is believed to only
directly affect CRP, it is possible that there is some unknown mechanism by which the CRP
gene affects fibrinogen not through affecting CRP levels and it is also possible that there
is population stratification. Consequently, we would like to consider a sensitivity analysis
that allows for violations of the assumptions of the CRP gene being a valid IV. See Freeman
et al. (2013a) for more details about the example.
We will use the same simulated data settings as Freeman et al. (2013a), the setting is:
Z = {1, 2, 3} with prob. (1/9, 4/9, 4/9); U ∼ N(0, 1.11 ∗ p ∗ 0.99)
X ∼ N(U + 0.1(Z − 2)
√
1.11 ∗ 9/4, 1.11 ∗ (1− p) ∗ 0.99); Y = 0.234X + U/
√
0.99
which gives
β = 0.234; ρ2ZD = 0.01; Var(X) = 1.11; Var(Z) = 4/9
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These parameters are based on studies of CRP and fibrinogen from CRP-CHD-Genetics-
Collaboration (CCGC), Burgess and Thompson (2010) and Burgess et al. (2012). We can
rewrite this model in an equivalent form which fits our model setting (A.1) with:
β = 0.234; δ = 0; γ = 0.1∗
√
1.11 ∗ 9/4; σ21 = 1.11∗p; σ22 = 1.11∗0.99; ρ =
√
p (2.28)
Freeman et al. (2013a) varied the parameter p in study, the larger p is, the more confounding
there is. We will consider p = 0.3, a moderate confounding effect, in most of the analysis
below.
First, without sensitivity analysis, we calculate the necessary sample size needed for rejecting
the null hypothesis with power greater than 0.8. If we use the t test based on asymptotic
normal distribution, then Freeman et al. (2013a) calculated the power formula as
n =
(zα/2 + zβ)
2V
λ2ρ2ZD
(2.29)
where V = σ21/Var(D). By formula (2.29), we need a sample size of 4301 if we want the
power greater than 0.8. However, if we use the AR test and plug the parameters (2.28)
into the power formula (2.17), then we would need a sample size of 7085, larger than the
sample size of 4301 suggested by (2.29). Although this would seem to suggest that using
the t-test based on the asymptotic normal distribution can reduce the sample size needed
compared to the AR test, the sample size needed for the t-test based on the asymptotic
normal distribution from (2.29) cannot be trusted while the sample size needed for the AR
test from (2.17) can be trusted. There are two reasons for this: (i) the nominal level of
the t-test based on the asymptotic normal distribution is not reliable for finite samples and
can be much greater than the actual level while the nominal level of the AR test is exactly
equal to the true level regardless of the sample size. (ii) the power formula (2.29) may not
be accurate for finite samples while the formula (2.17) is an exact formula.
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Figure 4: Data set is generated as σ1 = σ2 = 1, ρ = 0.9(0.1), β = 0, γ ∈ [0, 0.1], sd(Z) = 1
with sample size 5,000. Test with normal asymptotic distribution and standard AR test is
performed with nominal significance level α = 0.05. We calculate the average rejection rate
among 20,000 simulated data sets.
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We illustrate point (i) in Figure 4. In this figure, the null hypothesis is tested both using
the t-test based on the asymptotic normal distribution and the AR test where the null
hypothesis is true. The top panel considers a situation of large confounding while the bottom
panel considers a situation of small confounding. The strength of the IV is varied along the
x-axis. 10,000 data sets are simulated with 5000 observations each and the rejection rate is
displayed on the y-axis. The standard error of the rejection rate for a 0.05 level test from
10,000 simulations is smaller than
√
0.5 ∗ 0.5/10000 = 0.005. These simulations show that
the AR test always has level about 0.05, equal to its nominal level, while the t-test based
on the asymptotic normal distribution can have level way above its nominal level (an actual
level of 0.25 compared to the nominal level of 0.05 in the top panel for a weak IV) or level
way below its nominal level.
To illustrate point (ii) about the power formula (2.29) being less accurate than the power
formula (2.17), we consider the setting in Freeman et al. (2013a) described above and
simulated 10,000 data sets with 4301 observations from (2.28) with p = 0.3 and used the
t-test based on the asymptotic normal distribution. The power in the simulated data sets
is 0.7266 comparing to the number 0.8 that formula (2.29) said the power should be. In
contrast, when we simulated 10,000 data sets with 7085 observations from (2.28) with
p = 0.3 and used the AR test, the power in the simulated data sets was 0.8002 compared
to 0.8, as formula (2.17) said the power should be.
Now we consider sensitivity analysis using the AR test for model (2.28) with p = 0.3.
Suppose we would like to conduct a sensitivity analysis for δ ∈ [−0.01, 0.01], which means
a one unit change in the IV could change up to a 0.01 standard deviation of the structural
error. By the power formula (A.14), we need at least 8845 observations to achieve power at
least 0.8 under the favorable situation δ = 0.
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Figure 5: Sample size needed for achieving power>0.8 under different allowance of sensi-
tivity. The vertical line stands for the design sensitivity 0.0499. Here λ = 0.234, δ = 0, γ =
0.158, σ21 = 0.333, σ
2
2 = 1.0989, ρ = 0.548.
Figure 5 further explores the relationship between the sample size needed and the allowance
of sensitivity. We can see the curve starts flat for a while and then turns steep sharply.
This suggests that if the allowance of sensitivity is within a small range and we want to
perform sensitivity analysis, we do not need to increase the sample size much to achieve the
same power as without sensitivity analysis (δ = 0). However, after a certain threshold, even
allowing an extra little amount of sensitivity will result in a large increase of the sample
size. In this scenario the design sensitivity is 0.0499. If the range of sensitivity is greater
than (−0.0499, 0.0499), then the power will be close to zero no matter how large the sample
size.
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Table 1: Power for rare(common) variants under different sample size and sensitivity. We
set σ1 = σ2 = 1, ρ = 0.5, λ = 1. For rare variant, γr = 0.142, SD(Z)r = 0.071 and for
common variant, γc = 0.046,SD(Z)c = 0.218. In doing so rare and common variants have
the same concentration parameter under the same sample size. The numbers in parentheses
represent the power for common variants
n = 103 n = 104 n = 105 n = 106
Concentration Parameter 0.1 10 100 1000
∆=0 0.054 (0.054) 0.089 (0.089) 0.447 (0.447) 0.999 (0.999)
∆=0.02 0.054 (0.052) 0.086 (0.03) 0.377 (0.116) 0.997 (0.409)
∆=0.05 0.052 (0.042) 0.071 (0.016) 0.175 (0.001) 0.726 (0.000)
2.5.2 Sensitivity Analysis Using Rare vs. Common Variants as IVs
Two different types of genetic variants are common variants (the variant has frequency
> 1%) and rare variants (the variant has frequency < 1%). Common variants tend to have
small effects while rare variants can have larger effects. See Gibson (2012) and Zuk et al.
(2014) for discussion about rare vs. common variants. Most Mendelian randomization
studies have focused on using common variants but there is increasing opportunity for
using rare variants by making use of next generation sequencing (Zuk et al., 2014). Here we
compare the power of using a common variant vs. a rare variant. To make the comparisons,
we assume σ1 = σ2 = 1, ρ = 0.5, β = 1. Suppose the rare variant takes 0/1 with probability
0.995/0.005 and the IV effect is γr = 0.142 while the common variant takes 0/1 with
probability 0.95/0.05 and the IV effect is γc = 0.046. By choosing these IV effect sizes, the
rare and common variants have the same concentration parameter under the same sample
size. We can use (A.14) to calculate the power under different sample size and sensitivity.
We investigate the scenarios where the sample size is {103, 104, 105, 106} and the sensitivity
allowance is {(0, 0), (−0.02, 0.02), (−0.05, 0.05)}.
Table 1 shows the result. We see that if there’s no concern about the IV being invalid
(∆ = 0), i.e., no sensitivity analysis, the power for the rare and common variants are
exactly the same across different sample sizes since they have the same concentration pa-
rameter. However, if we allow for some of amount of IV invalidity and calculate the power
of sensitivity analysis, then the rare variant has better power than the common variant.
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As discussed in Section 2.4.2 and 2.4.3, for power of sensitivity analysis, the IV effect size
|γ|/σ2 plays a more important role concentration parameter. The rare variant in Table 1
has a larger IV effect size and consequently a higher power of sensitivity analysis. Another
thing to be noticed is that when ∆ = 0.02, the power of sensitivity analysis increases as
sample size increases for both rare and common variants. However, when ∆ = 0.05, the
power of sensitivity analysis decreases as sample size increases for common variant. This is
because the allowance of sensitivity is too large here such that the inequality (2.25) holds
and the power of sensitivity analysis goes to zero.
In summary, if a rare variant has a larger effect size than a common variant such that the
rareness and effect size balance each other to result in the same concentration parameter for
the rare and common variant, then the rare variant has larger power of sensitivity analysis
if there is concern about the IV being invalid.
2.6 Discussion
We have developed a method of sensitivity analysis and a power formula of sensitivity anal-
ysis for causal studies using IVs based on the AR test. Compared to previously developed
methods of sensitivity analysis for IVs, our method is robust to weak IVs. We have shown
that when designing causal studies using IVs in which there is concern that the IV might
not be perfectly valid, the key strength parameter one should consider about the IV is not
the IV’s concentration parameter, as has previously been done, but instead the effect size
of the IV on the exposure. This suggests that IVs based on rare genetic variants with large
effects will be less sensitive to bias than IVs based on common genetic variants with small
effects.
Currently, almost all Mendelian randomization studies have used common variants, but next
generation sequencing techniques such as whole exome sequencing facilitate the use of rare
variants in Mendelian randomization studies. Next generation sequencing techniques also
facilitate the possibility of using variation in the structure of a person’s chromosome (e.g.,
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deletions, duplications, copy-number variants, insertions, inversions and translocations) in
Mendelian randomization studies; such structural variation often has larger effects than
common SNP variants. Our findings suggest that Mendelian randomization studies can be
made less sensitive to bias by harnessing rare variants with large effect sizes as IVs.
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CHAPTER 3 : ivmodel: An R Package for Inference and
Sensitivity Analysis of Instrumental Variables
Models with One Endogenous Variable
3.1 Introduction
The instrumental variables (IV) method is a popular method to estimate the casual effect
of a treatment, exposure, or policy on an outcome when there is concern about unmeasured
confounding (Angrist et al., 1996b; Angrist and Krueger, 2001; Baiocchi et al., 2014b). IV
methods have been widely used in many field including statistics (Angrist et al., 1996b),
economics (Angrist and Krueger, 2001), genomics and epidemiology (Davey Smith and
Ebrahim, 2003), sociology Bollen (2012), psychology (Gennetian et al., 2008), political
science (Sovey and Green, 2011), and countless others. We also note that instrumental
variables have been used to correct for measurement errors (see Fuller (2006) for a full
treatment on measurement errors).
Informally speaking, IV methods rely on having variables called instruments which are
related to the exposure and are exogenous. An instrument is exogenous if it only affects the
outcome through the pathway of affecting the exposure (i.e. the instrument has no direct
effect on the outcome) and is independent of unmeasured confounders (see Section 3.2.3
for details). Typically, instruments either come from (i) natural experiments whereby the
instruments were naturally assigned to individuals at random or (ii) an actual randomized
experiment whereby the actual randomization mechanism is used as an instrument. For
example, in a field known as Mendelian randomization, natural genetic variations have
been used as an instrument to answer causal questions in epidemiology (Davey Smith and
Ebrahim, 2003, 2004; Lawlor et al., 2008b). Another example of the use of an instrument is
in the study of the effect of pregnant mother’s smoking on birth weight by Sexton and Hebel
(1984) and Permutt and Hebel (1989). Here, the instrument was the actual randomized
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encouragement assignment of mothers to one of the two groups, the first group where the
healthcare provider encouraged the mothers to stop smoking and the second group where
the healthcare provider did not provide such encouragement. Table 2 illustrates other
examples of instrumental variables, divided based on the source of the instruments. For
more examples, see Angrist and Krueger (2001) and Baiocchi et al. (2014b).
Outcome Exposure Instruments Reference
Natural experiments / Mendelian randomization
Earnings Years of schooling Proximity to college
when growing up
Card (1995)
Earnings Years of schooling Quarter of birth Angrist and Krueger
(1991)
Metabolic phe-
notypes
C-reactive protein
(CRP)
SNPs rs1800947,
rs1130864, rs1205
Timpson et al. (2005)
Blood pressure Alcohol intake Alcohol dehydrogenase
(ALDH2) genotype
Chen et al. (2008)
Randomized experiments / Encouragement designs
Birth weight Mother’s smoking Randomized encourage-
ment to stop smoking
Sexton and Hebel
(1984) and Permutt
and Hebel (1989)
Test scores Class size Randomized assignment
to different class sizes
Krueger (1999)
Table 2: Application of instrumental variables methods based on source of instruments.
Natural experiments/Mendelian randomization refer to instrumental variables studies where
the instruments come from natural sources, such as genes or calendar years. Randomized
experiments/encouragement designs refer to instrumental variables studies where the in-
struments represent actual randomization mechanisms.
Software for running instrumental variables methods varies widely depending on the pro-
gramming language. For example, in STATA, there are comprehensive and unified programs
to handle the most popular instrumental variables methods, most notably ivreg2 (Baum
et al., 2003, 2007) and STATA’s default program ivregress. In R, different instrumental
variables methods are implemented across different packages, for instance AER by Kleiber
and Zeileis (2008), sem by Fox et al. (2014), and lfe by Gaure (2013). Unfortunately, these
packages do not include (i) modern instrumental variables methods that provide confidence
intervals that are fully robust to weak instruments (see Section 3.4), (ii) sensitivity analysis
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methods that examine sensitivity of inference to violations of IV assumptions (see Section
3.5), and (iii) power calculations for IV analysis (see Section 3.6).
The goal of the paper is to present a package ivmodel that integrates and unifies R func-
tions to conduct a comprehensive instrumental variables analysis when there is one expo-
sure/endogenous variable. These functions include a general class of estimators known as
k-class estimators (see Section 3.3) and the corresponding standard errors, confidence in-
tervals, and p-values. The functions also integrate more modern approaches to IV analysis,
including two methods for confidence intervals that are fully robust to weak instruments
(Stock et al., 2002b), the Anderson and Rubin confidence interval (Anderson and Rubin,
1949b) and the conditional likelihood ratio confidence interval (Moreira, 2003). The pack-
age includes functions to calculate power. Finally, the package includes methods to conduct
sensitivity analysis to examine the sensitivity to the IV assumptions not holding. All these
functions are integrated into an R software package called ivmodel.
3.2 Instrumental Variables Model for One Endogenous Vari-
able
3.2.1 Notation
Let there be n individuals indexed by i = 1, . . . , n. For each individual i, we observe the
outcome Yi ∈ R, the exposure Di ∈ R, the L instruments Zi. ∈ RL, and the p covariates
Xi. ∈ Rp. Let Y = (Y1, . . . , Yn) ∈ Rn denote the vector of outcomes, D = (D1, . . . , Dn) ∈ Rn
denote the vector of exposures, Z ∈ Rn×L denote the matrix of instruments where the ith
row corresponds to the vector Zi., and X ∈ Rn×p denote the matrix of covariates where the
ith row corresponds to the vector Xi.. Let W = [Z : X] where W is an n by L+ p matrix
that concatenates the matrices Z and X.
For any matrixM , denote its transposeMT . Also, for any matrixM , let PM = M(M
TM)−1MT
be the orthogonal projection matrix onto the column space of M and RM be the residual
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projection matrix so that RM + PM = I, where I is an n by n identity matrix. We assume
that M has a proper inverse, so that (MTM)−1 is well-defined, unless otherwise stated.
3.2.2 Model
We assume the following linear structural model between the observed quantities, Yi, Di, Zi.,
and Xi.
Yi = Diβ +X
T
i. κ+ i, E(i|Zi., Xi.) = 0,VAR(i|Zi., Xi.) = σ2 (3.1)
This is the standard, single equation homoscedastic linear structural model in econometrics
(Wooldridge, 2010). Note that this is not the usual regression model in the sense that Di is
correlated with i. The parameter of interest is β, which is the causal effect of the exposure
Di on the outcome Yi (see next paragraph for more details on causal effects). The parameter
κ relates the covariates to the outcome. Note that Xi. can contain a value of 1 to represent
the intercept.
The parameters in model (3.1) can be given a causal interpretation under the potential
outcomes notation (Rubin, 1974b) where (3.1) represents the additive linear, constant effects
(ALICE) model in Holland (1988b). Let Y
(d,z)
i be the potential outcome if individual i were
to have exposure d, a scalar value, and instruments z, an L dimensional vector. Let D
(z)
i
be the potential exposure if the individual had instruments z. For each individual, only one
possible realizations of Y
(d,z)
i and D
(z)
i is observed, denoted as Yi and Di, respectively, based
on his/her observed instrument values Zi. and exposure Di. Then, for two possible values of
the exposure d′, d and instruments z′, z, we assume the following potential outcomes model
Y
(d′,z′)
i − Y (d,z)i = (d′ − d)β E(Y (0,0)i | Zi., Xi.) = XTi. κ (3.2)
In model (3.2), β represents the causal effect (divided by d′ − d) of changing the exposure
from d′ to d on the outcome. The parameter κ represents the impact of covariates on the
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baseline potential outcome Y
(0,0)
i . If we further define i = Y
(0,0)
i − E(Y (0,0)i | Zi., Xi.), we
obtain the observed data model in (3.1), thus providing the parameters in the observed
model in (3.1) a causal interpretation.
Note that in many works in econometrics literature, one makes additional assumptions
about the relationship between the endogenous variable Di, the instruments Zi., and the
covariates Xi., specifically
Di = Z
T
i. γ +X
T
i. κ˜+ ηi, E(ηi|Zi., Xi.) = 0,VAR(ηi|Zi., Xi.) = ω2 (3.3)
This “first stage” model in (3.3) is not necessary for all our methods in the ivmodel package.
In particular, the k-class estimators in Section 3.3 and the confidence interval for the An-
derson and Rubin test in Section 3.4 are valid without the first stage modeling assumption
in (3.3). However, the other methods presented in the paper require this assumption and
we introduce it in this section.
Similar to equation (3.2), we can provide a causal interpretation of the first stage model in
(3.3) as follows.
D
(z′)
i −D(z)i = (z′ − z)γ E(D(0)i | Zi., Xi.) = XTi. κ˜ (3.4)
In model (3.4), γ represents the causal effect (divided by z′− z) of changing the IV from z′
to z on the exposure. The parameter κ˜ represents the impact of covariates on the baseline
potential outcome D
(0)
i . As before, if we further define ηi = D
(0)
i − E(D(0)i | Zi., Xi.), we
obtain the observed data model in (3.3).
Without loss of generality and throughout the paper, we will use the simplified version of
the models in equations (3.1) and (3.3) where we project out the covariates X by the Frisch-
Waugh-Lovell Theorem (Davidson and MacKinnon, 1993b). Specifically, models (3.1) and
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(3.3) are equivalent to
Y ∗i = D
∗
i β + 
∗
i (3.5)
D∗i = Z
∗
i.γ + η
∗
i (3.6)
where
Y ∗ = RXY, D∗ = RXD, Z∗ = RXZ, ∗ = RX, η∗ = RXη
The superscripts Y ∗, D∗, Z∗ represent the outcome, the exposure, and the instruments
after controlling for the covariates X by the residual orthogonal projection RX defined in
Section 3.2.1. The equivalent models (3.5) and (3.6) allow us to concentrate on the target
parameter of interest, β, and simplify the derivations and expressions of the instrumental
variables methods presented in the paper. Note that as before, the model in (3.6), the
simplified version of the first stage model in (3.3), is not necessary for k-class estimators
and the Anderson and Rubin confidence intervals.
3.2.3 Assumption of Instrumental Variables
Under the model in (3.1), we make the standard assumptions in the instrumental variables
literature below (Wooldridge, 2010).
(A1) E(W TW ) is full rank.
(A2) Conditional on the covariates X, the instruments Z are associated with the exposure
D, E(ZTRXD) 6= 0
(A3) W is exogenous, E(W T ) = 0
Assumption (A1) is a standard moment condition on the matrix of exogenous variables
that include the covariates and the instruments. Assumption (A2) states that conditional
on the covariates X, the instruments are associated with the exposure. There are many
ways to test this assumption in practice, the most popular being the F statistic for the
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coefficients on the variables in Z being 0 when regressing D on X and Z. A strong associa-
tion between the instruments Z and the exposure D is desired to reduce the precision of an
IV estimator (Stock et al., 2002b). Instruments with strong associations are considered to
be strong instruments while instruments with weak associations are considered to be weak
instruments. For example, in the case of one instrument, an instrument is considered weak
if the F statistic is less than 10 (Stock et al., 2002b).
For assumption (A3), in the ALICE model, (A3) is satisfied if Z has no direct on D and
Z is independent of unmeasured confounders. Assumption (A3) is generally untestable in
that it’s impossible to check whether the exogenous variables Z and X are uncorrelated
with the structural error i, which is never observed. However, methods exist to partially
test this assumption if there are more than one instruments, L > 1, the most popular being
the Sargan’s test (Sargan, 1958). Under all the three assumptions (A1)-(A3), standard
econometric arguments show that the the model (3.1) is identified (Wooldridge, 2010).
Typically, practitioners assume that they have found instruments that satisfy (A1)-(A3)
(Angrist and Krueger, 2001). However, violations of these assumptions occur, especially
(A2) and (A3), and there has been progress in the literature to handle these violations
(Angrist and Krueger, 2001; Murray, 2006). For (A2), even if it is satisfied, but only weakly,
which is known as the weak instrument problem, the most commonly used instrumental
variables estimation method, two stage least squares (TSLS), produces biased estimates
of β in (3.1) (Nelson and Startz, 1990b; Staiger and Stock, 1997b; Stock et al., 2002b).
Thankfully, many statistical methods exist to provide robust and honest estimates of the
parameters in model (3.1) with weak instruments (Stock et al., 2002b) (see Section 3.4 for
details). Violations of (A3), known as the invalid instrument problem, is the case where
the instruments Z may have a direct effect on the outcome or when the instruments are
correlated with i. This problem has received less attention than the weak instrument
problem (Murray, 2006), but has recently been considered by Kolesa´r et al. (2013), Kang
et al. (2015), and Jiang et al. (2015).
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Throughout the paper, we assume that our instruments Z satisfy assumptions (A1)-(A3).
However, we discuss violations of (A2) and (A3) in Sections 3.4 and 3.5, respectively and
provide methods that can handle these violations.
3.3 k-Class Estimation and Inference
3.3.1 Definitions and General Properties
A class of estimators for β, called the k-class estimator and denoted as βˆk, is defined as
follows.
βˆk = (D
∗T (I − kPZ∗)D∗)−1D∗T (I − kPZ∗)Y ∗ (3.7)
Table 3 lists all the estimators that are k-class estimators, including the ordinary least
squares (OLS), two-stage least squares (TSLS), limited information maximum likelihood
(LIML), and Fuller’s estimator (FULL). In Table 3, kLIML is the minimum value of k of
the following equation
det
Y ∗T (I − kRZ∗)Y ∗ Y ∗T (I − kRZ∗)D∗
D∗T (I − kRZ∗)Y ∗ D∗T (I − kRZ∗)D∗
 = 0 (3.8)
k Name
k = 0 Ordinary least squares (OLS)
k = 1 Two-stage least squares (TSLS)
k = kLIML Limited information maximum likelihood (LIML)
k = kLIML − bn−L−p , b > 0 Fuller’s estimator (FULL)
Table 3: Different types of k-class estimator
Each k yields an estimator with unique properties, which will be discussed in detail in
Section 3.3.2. However, for all k-class estimators in equation (3.7), an estimate for the
standard error of βˆk is
̂VAR(βˆk) = σˆ2(D∗T (I − kPZ∗)D∗)−1, σˆ2 = (Y
∗ −D∗βˆk)T (Y ∗ −D∗βˆk)
n− L− p (3.9)
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As long as L and p are fixed, all k-class estimators are consistent so long as k → 1 as n→∞
in probability (Davidson and MacKinnon, 1993b). In addition, for fixed L and p, as long as
√
n(k− 1)→ 0 in probability as n→∞, the k-class estimator has the following asymptotic
Normal distribution (Amemiya, 1985)
βˆk − β√
̂VAR(βˆk)
→ N(0, 1) (3.10)
The asymptotic distribution in (3.10) allows us to test the hypothesis
H0 : β = β0, Ha : β 6= β0 (3.11)
by comparing the standardized deviate in (3.10) to the standard Normal (or the t distribu-
tion with degrees of freedom n− L− p). We can also create 1− α confidence intervals for
β based on βˆk, i.e.
(
βˆk − z1−α/2
√
̂VAR(βˆk), βˆk + z1−α/2
√
̂VAR(βˆk)
)
where z1−α/2 is the 1− α/2 quantile of the standard Normal distribution. We can alterna-
tively use the 1− α/2 quantile of the t distribution with degrees of freedom n− L− p.
3.3.2 Some Examples of k-class Estimators
The most well-known k-class estimator in instrumental variables is two-stage least squares
(TSLS) where k = 1 in (3.7), i.e.
βˆ1 = (D
∗TMZ∗D∗)−1D∗TMZ∗Y ∗
In addition to being consistent and having an asymptotic Normal distribution, TSLS is
efficient among all IV estimators using linear combination of instruments Z (Wooldridge,
2010). In fact, under the asymptotics rates of
√
n(k − 1) → 0 introduced in Section 3.3.1,
all k-class estimators have the same asymptotic Normal distribution as TSLS. Also, when
37
L = 1, TSLS and LIML produce identical estimates of β (Davidson and MacKinnon, 1993b).
However, despite having the same asymptotic Normal distributions, TSLS and other types
of k-class estimators, for instance LIML and FULL in Table 3, behave differently in finite-
samples. With weak instruments (i.e. near violations of (A2)), TSLS tends to be biased
towards OLS in finite sample. Even with large samples, TSLS can provide a very biased
estimate of the causal effect in the presence of weak instruments (Bound et al., 1995). In
contrast, LIML and FULL are more robust to violations of (A2) than TSLS (Stock et al.,
2002b). However, LIML has no finite moments of any order while TSLS has moments of up
to L−1. FULL corrects LIML’s lack of moments by having moments so long as the sample
size is large enough (Davidson and MacKinnon, 1993b).
Other types of k-class estimators exist and no single k-class estimator uniformly dominates
another in all settings (Davidson and MacKinnon, 1993b). However, in practice, the most
popular estimators are TSLS and LIML, with LIML having better robustness properties
with regards to weak instruments (Stock et al., 2002b; Mariano, 2003; Chao and Swanson,
2005)
3.4 Dealing with Weak Instruments: Robust Confidence In-
terval Estimation
In this section, we discuss the case when the instruments Z may nearly violate (A2), also
known as the weak instrument problem, and discuss two methods that are fully robust to
near violations of (A2).
Let M be an n by 2 matrix where the first column contains Y ∗ and the second column
contains D∗. Let a0 = (β0, 1) and b0 = (1,−β0) to be two-dimensional vectors and Σˆ =
MTRZ∗M/(n− L− p). Let Sˆ and Tˆ be two-dimensional vectors defined as follows.
Sˆ =
(Z∗TZ∗)−1/2Z∗TMb0√
bT0 Σˆb0
, Tˆ =
(Z∗TZ∗)−1/2Z∗TM Σˆ−1a0√
aT0 Σˆ
−1a0
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We also define the following scalar values, Qˆ1, Qˆ2, and Qˆ3.
Qˆ1 = Sˆ
T Sˆ, Qˆ2 = Sˆ
T Tˆ , Qˆ3 = Tˆ
T Tˆ
Based on Qˆ1, Qˆ2, and Qˆ3, we define two tests of the hypothesis in equation (3.11) that
are fully robust to violations of (A2), the Anderson and Rubin test (Anderson and Rubin,
1949b), and the conditional likelihood test (Moreira, 2003).
AR(β0) = Qˆ1/L (3.12)
CLR(β0) =
1
2
(Qˆ1 − Qˆ3) + 1
2
√
(Qˆ1 + Qˆ3)2 − 4(Qˆ1Qˆ3 − Qˆ22) (3.13)
Much work has shown that these two tests are fully robust to weak instruments (Staiger
and Stock, 1997b; Stock et al., 2002b; Moreira, 2003; Dufour, 2003; Andrews et al., 2006b).
Between the two tests, there is no uniformly most powerful test under weak instruments,
but Andrews et al. (2006b) and Mikusheva (2010) suggest using (3.13) due to its generally
favorable power compared to (3.12) in most cases when weak instruments are present.
However, the Anderson-Rubin test is the simplest of the two tests in that under a Normality
error assumption (see next paragraph), it can be written as a standard F-test in regression
where the outcome is RZ∗(Y −Dβ0), the regressors are Z∗, and we are testing whether the
coefficients associated with Z∗ are zero or not with the standard F-test. Also, unlike the
Anderson and Rubin test in (3.12), the conditional likelihood ratio test in (3.13) requires
the first stage modeling assumption in (3.3) (Dufour, 2003).
We can invert both tests in equation (3.12) and (3.13) to obtain 1− α confidence intervals
that are fully robust to weak instruments, i.e. {β : AR(β0) ≤ FL,n−L−p,1−α} for the
Anderson and Rubin confidence interval and {β : CLR(β0) ≤ q1−α} for the conditional
likelihood ratio test. Here, FL,n−L−p,1−α is the 1 − α quantile of the F distribution with
degrees of freedom L and n − L − p and q1−α is the 1 − α quantile of the the conditional
likelihood ratio test. The F distribution for the Anderson and Rubin test is based on an
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assumption about Normality of the errors in model (3.1) and our package ivmodel currently
uses the F distribution. However, one can also use the χ2 distribution as an asymptotic
approximation should the Normality assumption be unreasonable in the data. As for the
distribution that underlies the conditional likelihood ratio test and the details on q1−α, see
Andrews et al. (2007).
3.5 Dealing with Possibly Invalid Instruments: Sensitivity
Analysis
Morgan and Winship (2007b) showed that assumption (A3) cannot be completely tested.
However, there is often concern that a putative IV is invalid in applications. In these cases,
a sensitivity analysis can be used to examine the sensitivity of inferences to violations of
(A3). Here we assume that there is only one IV (L = 1) in the study and this IV may be
invalid to some degree.
There is some previous work on sensitivity analysis for IV studies, see DiPrete and Gangl
(2004b), Small (2007b), Kolesa´r et al. (2011b) and Conley et al. (2012b). These papers all
use test statistics which are based on the TSLS estimator having an approximately normal
distribution, which breaks down in the presence of weak instruments (instruments that
are weakly associated with the exposure), see Nelson and Startz (1990b). Our sensitivity
analysis uses the AR test statistic because of the following properties: the AR test is robust
to a weak instrument; the AR test is uniformly most powerful among all unbiased tests
(Moreira, 2001b) and the AR test is uniformly most powerful among all invariant similar
tests (Andrews et al., 2006b).
We revise the model in Section 4.3 to add the feature of invalid IV. For model (3.2), assume
that Zi violates the assumption (A3) so there is another term δσ(z
′ − z) on the equation’s
right side:
Y
(d′,z′)
i − Y (d,z)i = (d′ − d)β + δσ(z′ − z), E(Y (0,0,0)i | Zi., Xi.) = XTi. κ (3.14)
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Here σ is the standard variation of i = Y
(0,0,0)
i − E(Y (0,0,0)i | Zi., Xi.), which is a scaling
parameter. δ measures how much the IV Zi. violates the assumption (A3). Further assume
the sensitivity parameter is within a known range, δ ∈ (δ, δ¯). Then the model for sensitivity
analysis becomes:
Yi = Diβ+X
T
i. κ+δσZi.+i, E(i|Zi., Xi.) = 0, VAR(i|Zi., Xi.) = σ2, δ ∈ (δ, δ¯) (3.15)
If the error term has a normal distribution i ∼ N(0, σ2), then hypothesis (3.11) can be
tested by using the AR test statistic AR(β0) in equation (3.12). Under H0, AR(β0) has a
non-central F distribution :
AR(β0) ∼ F1,n−p−1,δ2Z∗TZ∗ (3.16)
Although δ is unknown and consequently we don’t known exact the distribution of AR(β0)
under H0, we can define ∆ = max(|δ|, |δ¯|) and construct an interval that provides at least
1− α confidence:
CI1−α = {β : AR(β0) < F1,n−p−1,∆2Z∗TZ∗;1−α} (3.17)
For our sensitivity analysis, equation (3.17) is used for the hypothesis test. More details
are provided in Jiang et al. (2015).
3.6 Power
If the research goal is to find evidence for an exposure effect, then we would like to know the
power of rejecting the null hypothesis H0 : β = β0 when the true exposure effect is under the
alternative β−β0 = λ 6= 0. With a power formula, researchers can decide how large a sample
to collect to achieve a certain power. Freeman et al. (2013b) presents a power formula for
using the asymptotic normal distribution of TSLS estimator to do hypothesis test. Jiang
et al. (2015) provides a power formula for the AR test and sensitivity analysis. These three
different power formulas are included in ivmodel. By inverting the power formula, we can
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calculate the sample size needed to achieve a certain power. These sample size calculation
functions are also included in ivmodel. The three different approaches to a power formula
rely on different assumptions, which will be discussed in the following paragraphs.
Freeman et al. (2013b) assumes there is only one IV(L = 1) and there are no observed
covariates X(p = 0), which is model (3.1) with κ = 0. Asymptotically, the TSLS estimator
has a normal distribution:
βˆTSLS ∼ N
(
β,
σ2
n · VAR(D) · ρZD
)
(3.18)
If the true exposure effect is β − β0 = λ, then the power of testing hypothesis (3.11) is:
Power = 1 + Φ
(
−zα/2 −
λρZD
√
n · VAR(D)
σ
)
− Φ
(
zα/2 −
λρZD
√
n · VAR(D)
σ
)
(3.19)
where α is the desired significance level of the test (usually 0.05), Φ is the cumulative
distribution function of the standard normal distribution, zα is the value satisfies Φ(−zα) =
α and ρZD is the correlation between Z and D.
The AR test is based on model (3.1). In order to calculate the exact power, we need to
have another model between the exposure and IV, as stated in (3.3) and make the bivariate
normality assumption for the error (i, ηi). The extended model is summarized as follows.
Y ∗ = D∗β + ∗
D∗ = Z∗γ + η∗
Y ∗ = RXY, D∗ = RXD, Z∗ = RXZ, ∗ = RX, η∗ = RXη
(, η) ⊥ Z; (i, ηi)T ∼ N (0,Σ) ; Σ =
 σ2 ρσω
ρσω ω2
 rank(X) = p
(3.20)
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If the true exposure effect is β − β0 = λ, then the power of testing hypothesis (3.11) is:
Power = 1−Ψ
1,n−p−L, (γT Z∗T Z∗γ)λ2
σ2+2ρσωλ+ω2λ2
(F1,n−p−L;1−α) (3.21)
where Fa,b;1−α is the 1 − α quantile of F distribution with degrees of freedom a and b.
Ψa,b,k(·) is the cumulative distribution function of the non-central F distribution with degree
of freedom a, b and non-central parameter k.
The sensitivity analysis relies on model (3.15) with one possibly invalid IV. To calculate its
power, the model (3.3) and normality assumption is still needed. The extended model is
similar to (3.20).
Y ∗ = D∗β + δσZ∗ + ∗
D∗ = Z∗γ + η∗
Y ∗ = RXY ; D∗ = RXD; Z∗ = RXZ; ∗ = RX; η∗ = RXη;
(, η) ⊥ Z; (i, ηi)T ∼ N (0,Σ) ; Σ =
 σ2 ρσω
ρσω ω2
 rank(X) = p
(3.22)
If the true exposure effect is β−β0 = λ and it is a favorable situation where the instrument
is valid (δ = 0) but we want to allow for the possibility that the instrument is invalid in
the range δ ∈ (−∆,∆) (Rosenbaum, 2010b), then the power of being able to reject the null
hypothesis for all δ ∈ (−∆,∆) is:
Power = 1−Ψ
1,n−p−1, λ2γ2Z∗T Z∗
σ2+2ρσωλ+ω2λ2
(F1,n−p−1,∆2Z∗TZ∗;1−α) (3.23)
where Fa,b,c;1−α is the 1 − α quantile of the non-central F distribution with degree of
freedom a, b and non-central parameter c. (3.23) is called the power of sensitivity analysis
for sensitivity ∆.
When the sample size is small or moderate and the IV is weak, the asymptotic test (3.18)
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based on the two stage least squares estimator can have highly inflated Type I error and
should be avoided (Jiang et al., 2015). For these settings, Jiang et al. (2015) recommend
using the AR test and its associated power formula (3.21).
3.7 Application
In this section, we illustrate the application of ivmodel with the data set from Card (1995).
The data is from the National Longitudinal Survey of Young Men (NLSYM), which has
n = 3010 individual observations and 35 variables. We want to estimate the causal effect of
education (educ) on log earnings (lwage). The IV is a binary variable indicating whether
the individual grew up in a place with a nearby 4-year college (nearc4). There are also
some exogenous variables included in the data (exper, expersq, black, south, etc).
3.7.1 Ivmodel Class and the Basic Usage
As discussed above, we specify the outcome Y is log earnings (lwage); the exposure D
is (educ); the IV Z is (nearc4); other exogenous variables X is (exper, expersq, black,
south). Then we can use ivmodelFormula() to generate an ivmodel class object which
assembles various IV methods.
R> cardfit = ivmodelFormula(lwage ~ educ + exper + expersq + black + south |
R+ nearc4 + exper + expersq + black + south, data=card.data)
However, when there are many exogenous variables, the formula style of input is not con-
venient, then we can use function ivmodel() instead of ivmodelFormula():
R> Y = card.data[,"lwage"]
R> D = card.data[,"educ"]
R> Z = card.data[, "nearc4"]
R> Xname = c("exper", "expersq", "black", "south", "smsa",
R+ paste("reg", 661:668, sep=""), "smsa66")
R> X = card.data[, Xname]
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R> cardfit = ivmodel(Y=Y, D=D, Z=Z, X=X)
After ivmodel object is generated, use print.summary.ivmodel() to display the informa-
tion:
R> summary(cardfit)
Call:
ivmodel(Y = Y, D = D, Z = Z, X = X)
sample size: 3010
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
First Stage Regression Result:
F=13.25579, df1=1, df2=2994, p-value is 0.00027634
R-squared=0.004407934, Adjusted R-squared=0.004075405
Residual standard error: 1.940537 on 2995 degrees of freedom
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Coefficients of k-Class Estimators:
k Estimate Std. Error t value Pr(>|t|)
OLS 0.000000 0.074693 0.003498 21.351 <2e-16 ***
Fuller 0.999666 0.127501 0.052708 2.419 0.0156 *
LIML 1.000000 0.131504 0.054964 2.393 0.0168 *
TSLS 1.000000 0.131504 0.054964 2.393 0.0168 *
---
Signif. codes: 0 ’***’ 0.001 ’**’ 0.01 ’*’ 0.05 ’.’ 0.1 ’ ’ 1
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
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Alternative tests for the treatment effect under H_0: beta=0.
Anderson-Rubin test:
F=5.415279, df1=1, df2=2994, p-value=0.020028
95 percent confidence interval:
[ 0.0248048359650698 , 0.284823593339102 ]
Conditional Likelihood Ratio test:
Test Stat=5.415279, p-value=0.020028
95 percent confidence interval:
[0.0248043722947518, 0.284824550721994]
There are four sections in the display. The first section is a recall for the ivmodel expression
and the sample size. The second section summarizes the first stage regression between the
IV and exposure. Here the F statistic is 13.25579, which is greater than 10, indicating the
IV is not weak (Stock et al., 2002b), so TSLS estimator will not be largely biased. The third
section lists the results for several k-class estimator. The default k’s are k = 0 (OLS), k = 1
(TSLS), and k’s associated with LIML and Fuller. Here we only have one IV, so TSLS and
LIML are the same. The estimated causal effect for TSLS is 0.1315, with a significant p
value 0.0168. This can be interpreted as when increasing education by 1 level, the earnings
will increase by 13%. The last section provides the AR and CLR confidence intervals, which
are robust even for weak IVs (although in this case the IV is not weak). Here we can see
both confidence intervals don’t cover 0, so the causal effect is significant even under robust
tests. The p value for robust test is 0.02, larger than 0.0168 in TSLS, we are trading the
test power with robustness.
The method confint.ivmodel() calculates the confidence interval for various IV methods.
Similarly, we also provide methods coef.ivmodel(), fitted.ivmodel(), residuals.ivmodel().
R> confint(cardfit)
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2.5% 97.5%
OLS 0.06783385 0.08155266
Fuller 0.02415275 0.23084946
LIML 0.02373345 0.23927422
TSLS 0.02373345 0.23927422
AR 0.02480484 0.28482359
CLR 0.02485469 0.28472068
3.7.2 Power Calculation and Sample Size
Suppose the TSLS estimator is the real causal effect β = βˆTSLS . In this case, if we still
test the null hypothesis that there is no causal effect H0 : β = 0, then the probability to
reject H0 is defined as the power. ivmodel provides power calculation function IVpower()
for TSLS, AR test and sensitivity analysis. See section 3.6 for details of the power formula.
In this example, the power of TSLS is 0.668 and the power of AR test is 0.643.
R> IVpower(cardfit); IVpower(cardfit, type="AR")
[1] 0.6676418
[1] 0.6432517
We can compare the power of TSLS and AR under different sample size, Figure 6 is the
output graph.
R> ngrid = (1:100)*100
R> plot(IVpower(cardfit, n=ngrid)~ngrid, type="l", lty=1, ylab="power")
R> points(IVpower(cardfit, n=ngrid, type="AR")~ngrid, type="l", lty=2)
R> legend("bottomright", legend=c("TSLS", "AR"), lty=c(1, 2))
Usually we want a power of 0.8 or higher. In experimental design, we can increase the sample
size needed to achieve the power threshold. IVsize() calculates the minimum sample size
needed for achieving a certain power threshold. In this example, we need 4,125 sample size
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Figure 6: Complete.
for TSLS and 4,362 sample size for AR test.
R> IVsize(cardfit, power=0.8); IVsize(cardfit, power=0.8, type="AR")
[1] 4125
[1] 4362
3.7.3 Sensitivity Analysis
There is usually concern that the IV may be invalid, in this data, there may have confound-
ing factors like geographic or social features that affects both the existence of a nearby
4-year college and the earnings, but not through education. A sensitivity analysis can be
performed in such case. Assume that if we hold education and IV fixed, the variation re-
mained in the earnings is σ. We assume the range for sensitivity is δ ∈ (−0.03, 0.03), which
means a unit change in the invalid IV near4c will change the outcome lwage by up to 0.03σ
in a way not related to the exposure educ. To perform the sensitivity analysis, just specify
the sensitivity range in ivmodel():
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R> cardfit2=ivmodel(Y=Y, D=D, Z=Z, X=X, deltarange=c(-0.03, 0.03))
R> summary(cardfit2)
..................
..................
..................
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Alternative tests for the treatment effect under H_0: beta=0.
Anderson-Rubin test:
F=5.415279, df1=1, df2=2994, p-value=0.020028
95 percent confidence interval:
[ 0.0248048359650698 , 0.284823593339102 ]
Sensitivity analysis with deltarange [ -0.03 , 0.03 ]:
non-central F=5.415279, df1=1, df2=2994, ncp=0.4390019, p-value=0.049504
95 percent confidence interval:
[ 0.000347142651197386 , 0.340944347177351 ]
Conditional Likelihood Ratio test:
Test Stat=5.415279, p-value=0.020028
95 percent confidence interval:
[0.0248043722947518, 0.284824550721994]
The sensitivity analysis is reported in the last section when printing the summary informa-
tion. The p-value is 0.049, suggesting that education still has a significant positive effects
towards earnings even if the IV may be invalid at a certain degree. The power is 0.261 and
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we need 17,869 sample size to have a power of at least 0.8.
R> IVpower(cardfit2, type="ARsens"); IVsize(cardfit2, power=0.8, type="ARsens")
[1] 0.2615532
[1] 17869
3.8 Summary
The package ivmodel provides a unified implementation of instrumental variables methods
in the case of one endogenous variable. The package contains a general class of estimators,
k-class estimators. The package also contains methods that can deal with violations of
instrumental variables assumptions, (A2) and (A3). First, for violations of (A2), the package
contains two confidence intervals that are fully robust to weak instruments. For (A3), the
package contains methods for sensitivity analysis for the range of violation. The package
also contains power formulas to guide designs of future instrumental variables studies. As
our data example in Section 3.7 demonstrated, our package provides an easy and unified
way of conducting a comprehensive instrumental variables analysis with data where there is
one endogenous variable, along with ways to assess sensitivity to violations of instrumental
variables assumptions and to compute power.
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CHAPTER 4 : Hidden Markov Model for Estimating
Financial Incentive Effects towards Healthy
Behavior
4.1 Introduction
Patient’s poor adherence to medications has large impact on their health outcomes and
health costs (Peterson et al., 2003). Especially for chronic conditions where long-term
medication is needed, the medication will be most efficient only within a short range and
patient’s consistent adherence is the key to keep the doses in that level. Besides medica-
tions, physicians may recommend people to have a minimum level of physical exercise (Go
et al., 2013). However, it is difficult for people to maintain these healthy behaviors, either
medications or exercises (Jackevicius et al., 2002; Bravata et al., 2007).
There are different methods to improve people’s adherence of healthy behavior, such as
implementing the support which comes from peers with the same chronic condition (Glasgow
and Toobert, 1988); using an electronic medication monitoring system with a daily alarm
to remind people take medication as scheduled (Kimmel et al., 2016a); using financial
incentives to enhance adherence (Loewenstein et al., 2012; Ries, 2012). For the studies of
financial incentives, previous literature only compares the overall effect among treatment
group and control group. In this paper, we will focus on analyzing the dynamic effect of
lottery-based financial incentive implemented with long-term medication. More specifically,
every participant will be informed of a lottery result on a daily basis, if he does adhere on
that day and he wins the lottery, he can take the money. If he doesn’t adhere but wins
the lottery, he cannot take the money. We want to study how does the outcome of lottery
dynamically affect patient’s adherence. Our study interest can better address questions
like if we change the lottery result on a particular day, how much will this affect patient’s
behavior. Such result can be used for designing an efficient lottery incentive system with
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limited budget.
We propose Hidden Markov Model(HMM) with random effects to model participant’s
longitudinal adherence and lottery results. The hidden state is the participant’s ten-
dency(probability) to adhere on each day and the combination of participant’s outcome
and lottery result determines the tendency to adhere next day. HMM is well-suited to
model the dynamic effects in longitudinal data and there are similar works of HMM in
behavioral economics, such as Shirley et al. (2010); Altman (2007). EM algorithm and
Baum-Welch algorithm (McLachlan and Krishnan, 2007) are used to find the maximum
likelihood estimation and 200 bootstrap data are created to construct the confidence in-
terval. The estimation results are compared across 3 different trials with similar lottery
incentive system.
The rest of the paper is organized as follows: Section 4.2 describes the data source and trail
protocol. Section 4.3 introduces our assumptions and models. Section 4.4 compares the
estimation results and Section 4.5 summaries the results and discussions.
4.2 Data source and trial protocols
Our study will be based on three different clinical trials, which share the similar protocols
that patients are monitored by a remote device to check whether they adhere to the med-
ication/exercise each day. Each study also has a similar structure of daily lottery system
as the intervention of financial incentives. Notice that there is no control group selected in
the trial, every patient takes the lottery. We will analysis the dynamic effect of financial
incentives in each trail and compare the results among these three cohorts.
4.2.1 Walking steps
207 eligible participants from the University of Pennsylvania are selected to this 13-week
trial which starts in Mar. 2014. They are all age 18 years or older and have a body mass
index(BMI) of at least 27kg/m2. The BMI threshold is chosen so the sample can represent
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overweight people. Participants are given a goal of achieving at least 7,000 steps per day
and they have a smartphone to track the adherence. The lottery system is designed such
that every day each participant independently has 1% chance to win $50, 18% chance to
win $5. Participant will be informed of the lottery result everyday, but they can collect
the money only if they do adhere on that day. More details can be found from Patel et al.
(2016), notice that we exclude the control group in the original paper.
4.2.2 Glucose reading
102 African American veterans with persistently poor glycemic control are identified from
the Philadelphia VA Medical Center for this 24-week trial starting in Mar. 2011. They are
from two arms, one arm receives financial incentives and the other receives both financial
incentives and peer mentors. Participants use the provided glucometer to measure and
report their fasting glucose values. If they adhere to healthy behavior, the reading values
can be controlled within 80-140mg/dl. Lottery system will be implemented to both arms.
In financial incentive arm, participant has 1% chance to win $100, 18% chance to win $10
everyday. They will be informed of the lottery result and they can take the money only if
they adhere on that day. In financial incentive and peer mentor arm, the participant with
split the winning lottery with their mentor, so he has 1% chance to win $50, 18% chance to
win $5 everyday. More details can be found as the study NCT01125969 stated in Lorincz
et al. (2013), notice that we exclude two arms which don’t have financial incentives.
4.2.3 Warfarin dose
119 patients are recruited from the Hospital of the University of Pennsylvania and the
Philadelphia Veterans Affairs Medical Center from Nov. 2009 to May 2012. They all have
an expected duration of warfarin therapy of at least 6 months and they all have at least one
international normalized ratio out of range within 90 days prior to enrollment. Patients are
given an electronic medication monitoring system to measure their adherence to warfarin
therapy everyday. Lottery system is implemented so that patient has 1% chance to win
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$100 and 20% to win $10. Patient will be informed of the daily lottery result but they can
take the money only if they adhere on that day. What different from previous two trials
is that if the monitor gets disconnected, the lottery result cannot be delivered, which will
be discussed in more details in the model section. More details can be found from Kimmel
et al. (2016b), notice that we only use the two out of four groups which receive lottery in
the original paper.
4.3 HMM for dynamic incentive
Current research (Patel et al., 2016; Lorincz et al., 2013; Kimmel et al., 2016b) studies the
overall effect of financial incentive by comparing the treatment group and control group
after the whole trial ends. In this paper, we will focus on the dynamic effect of the daily
financial incentive, e.g., how does it affect participant’s behavior along the timeline. In this
section, the data from walking step trial will be used for illustration, the other two trials
share the same model structure.
4.3.1 The hidden state and lottery effect
Suppose for patient i the trial lasts Ti days. The lottery result is observed as Li =
{L1i , . . . , LTii }, there are three possible outcomes of Lti, not win (Lti = N), win small
$5 (Lti = S) or win big $50 (L
t
i = B). The patient’s adherence is noted as Ai =
{A1i , . . . , ATii }, Ati ∈ {A,N}. Ati = A means patient i adhered on day t. On each day
the patient has a certain probability to adhere, we will use Xi = {X1i , . . . , XTii } to represent
this. This Xti is the unobserved hidden state which describes patient’s tendency to adhere
on day t. The patient will first decide to adhere or not, or the value of Ati, according to X
t
i ,
then the lottery result Lti will be drawn and sent to the patient.
We assume that the combination of lottery result Lti and adherence A
t
i will affect the
patient’s tendency to adhere on the next day (Xt+1i ). More specifically, the patient will
only receive money if he adheres and wins the lottery. This is a direct financial incentive. If
he does not adhere but wins the lottery, he will be informed that he would have won XXX
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if he adhered. In this scenario, there is still regret effect of sending out the lottery result
(Chapman and Coups, 2006; Zeelenberg and Pieters, 2004). In total, there are six possible
combinations of adherence and lottery result {NN,NS,NB,AN,AS,AB} (e.g., NB means
not adhere and win big), each combination has a different effect towards patient’s tendency
to adhere in the next day.
4.3.2 The models
Ideally, the tendency to adhere Xti would be best modelled as a probability in [0, 1]. Here for
simplicity and practicality, we assume that Xti only has two states, X
t
i = 1 means patient i
is in low adherence state and Xti = 2 represents the high adherence state. Parameters θ1, θ2
are used to model the probability of adherence via a logit function and δi is a heterogeneity
parameter to modify the probability in the individual level. Therefore the probability
function for patient’s adherence can be written as:
P (Ati = A | Xti ) =
exp(θXti + δi)
1 + exp(θXti + δi)
; θ1 < θ2,
∑
i
δi = 0. (4.1)
To model the dynamic effects of lottery towards the hidden state, we assume that the hidden
state Xti varies from day to day and has Markov property. Then the key is to model the
transition probability from Xti to X
t+1
i . In the beginning of this section we discussed that
each combination AtiL
t
i has a different effect towards the transition of hidden states, since
there are only two states for Xti , we will directly model the 2 × 2 probability transition
matrix as
P (Xt+1i | Xti , Ati, Lti) = QAtiLti(X
t
iX
t+1
i ) (4.2)
where (XtiX
t+1
i ) refer to the corresponding entry of matrix QAtiLti . There are six probability
transition matrices in total, {QNN , QNS , QNB, QAN , QAS , QAB}. The row sum of each
matrix should be 1, so there are 2 free parameters in each matrix, and 12 degrees of freedom
in total in this part of model. The difference between these probability transition matrices
reflects the dynamic effect. Also, parameter p is used for the distribution of patient’s hidden
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state in the first day X1i as:
P (X1i = 1) = 1− p; P (X1i = 2) = p. (4.3)
Equation 4.1, 4.2 and 4.3 together are the complete HMM model we constructed, Figure 7
describes the probability relationship between variables and the corresponding parameters
in the probability function are in parentheses.
Figure 7: The HMM modeling the dynamic effect of lottery towards patient’s tendency to
adhere.
4.3.3 Model variation for the other trials
In glucose trial, the financial incentive and peer mentor arm only receive half lottery amount
as the pure financial incentive arm. Here we will not differentiate these two arms, win
$100/$50 are treated the same as win big , win $10/$5 are treated the same as win small.
In doing so, the model for glucose trial is exactly the same as the walking step trial, so
results can be compared across trials.
In warfarin trial, the electric monitor given to patient may get disconnected for a short
while, patient can not receive any lottery result during those days. Therefore besides the
six types of combination AtiL
t
i, we assume that the transition matrix is QNone when patient
does not hear from the lottery result. This can also be viewed as a different type of effect.
Besides this, all other parts of the model are the same. There is also about 3% missing
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data, we assume that they are missing at random.
4.4 Model fits and comparison
4.4.1 Fitting the model
We will use a standard approach to fit the HMM model derived in last section, which has
the following steps:
(i) Initialize all the parameters.
(ii) Use Baum-Welch algorithm to calculate the conditional probability P (Xti | Li,Ai) and
P (Xti , X
t+1
i | Li,Ai).
(iii) Use the above conditional probability and initialized parameter values to maximize
the log likelihood function and update the parameter values.
(iv) Repeat step ii and iii until parameters converge.
The above steps give us a point estimation for the parameters and bootstrap will be used
to construct the 95% confidence interval for each parameter. We sample the same number
of patients with replacement to construct a bootstrap data and get a bootstrap estimation.
This procedure is repeated for 200 times and the 95% confidence interval is constructed
from the 200 bootstrap estimations.
4.4.2 Model Interpretation
The point estimation and 95% confidence interval for the parameters in equation 4.1, 4.2
and 4.3 are listed as below:
p = 0.23 (0.04, 0.56); θ1 = −1.88 (−2.73,−1.81); θ2 = −0.59 (−1.12, 0.03); (4.4)
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QNN =
1.00(0.48, 1.00) 0.00(0.00, 0.52)
0.40(0.17, 0.93) 0.60(0.07, 0.83)
 ; QNS =
1.00(0.61, 0.99) 0.00(0.01, 0.39)
0.40(0.20, 0.85) 0.60(0.15, 0.80)

(4.5)
QNB =
1.00(0.10, 1.00) 0.00(0.00, 0.90)
0.00(0.00, 0.99) 1.00(0.01, 1.00)
 ; QAN =
0.26(0.06, 0.62) 0.74(0.38, 0.94)
0.18(0.01, 0.41) 0.82(0.59, 0.99)

(4.6)
QAS =
0.40(0.00, 0.72) 0.60(0.28, 1.00)
0.08(0.00, 0.47) 0.92(0.53, 1.00)
 ; QAB =
0.00(0.00, 0.20) 1.00(0.80, 1.00)
0.00(0.00, 0.52) 1.00(0.48, 1.00)

(4.7)
We can see that when patient does not adhere, no matter what the lottery result is, the
probability that he will transit from low to high hidden state is 0 (the upper left entries for
transition matrix QNN , QNS , QNB are 1), therefore it’s hardly to believe that regret has a
significant effect towards patient’s adherence in walking step trial. On the other hand, when
patient does adhere, the probability of transiting from low/high to high state increases as
the lottery outcome rises. This would suggest that the real financial incentive may have
some effect towards patient’s adherence.
However, it’s hard to give a straightforward interpretation if we only look at the transition
matrix. We need to interpret the result in an easier way. Notice that the hidden state Xti
and adherence Ati will be determined first, then an independent lottery will be drawn. We
can devide patients into 4 groups: the patient is in low state and adhered; in low state
and did not adhere; in high state and adhered; in high state and did not adhere. Then for
each group, given a lottery result on that day, we can calculate the patient’s probability to
adhere in the next day. Table 4 shows the probability and also the confidence interval. In
doing so, we directly associate the effect of lottery result towards the probability to adhere
next day. With this result, people can design an efficient lottery system that increases user’s
adherence within limited budget for lottery.
In table 4, for patients who did not adhere, no matter he was in low or high hidden state, his
probability to adhere will not change much as lottery result varies. This also suggests that
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Table 4: Given patient’s hidden state and adherence, the probability to adhere in the next
day under different lottery result. Parenthesis is the 95% confidence interval.
not win win small win big
low & adhere 0.38(0.31, 0.42) 0.36(0.29, 0.44) 0.43(0.37, 0.52)
low & not adhere 0.25(0.21, 0.32) 0.25(0.21, 0.30) 0.25(0.20, 0.41)
high & adhere 0.40(0.36, 0.44) 0.42(0.35, 0.46) 0.43(0.36, 0.51)
high & not adhere 0.36(0.25, 0.43) 0.36(0.25, 0.41) 0.43(0.23, 0.52)
there is no significant regret effect in the trial. We further compare the p-value of testing
whether different lottery result has significant effect towards the patient’s future adherency.
Table 5 shows the result.
Table 5: P-value of comparing different lottery result’s effects toward patient’s probability
to adhere given patient’s hidden state and adherence.
win big - win small win small - not win win big - not win
low & adhere 0.015 0.515 0.020
low & not adhere 0.430 0.545 0.450
high & adhere 0.065 0.305 0.050
high & not adhere 0.255 0.430 0.215
There are 3 entries with p-values smaller than the threshold 0.05. For patient in low state
and does adhere, win big is significantly better than win small or not win in terms of
probability to adhere in next day. For patient in high state and does adhere, the only
significance found is win big v.s. not win. In this walking step trial, we think the financial
incentive will be useful if the patient actually adheres and receives the money. No regret
effect is found.
4.4.3 Model comparison
We also perform the same model fitting procedure to the other two trials. Here we will just
report the table of p-values as in Table 5.
Table 6 shows the p-value for glucose trial, which has two significant entries. The result
here is very different from the result in walking trial. We find a significance in regret effect,
but do not find significance in the effect of real financial incentive. Also the more frequent,
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win small result is better than the less frequent, win big result.
Table 6: P-value for comparing different lottery results using the data from glucose reading
trial.
win big - win small win small - not win win big - not win
low & adhere 0.555 0.160 0.495
low & not adhere 0.865 0.020 0.780
high & adhere 0.290 0.395 0.245
high & not adhere 0.350 0.030 0.195
Table 7 shows the p-value for warfarin trial. In this trial we fail to find any significant effect.
This may be that there are part of data missing in this trial and also patients in this trial do
not have the same length of observation period, some patients have very few observations.
These can lead to a wider confidence interval and less power to find the significance.
Table 7: P-value for comparing different lottery results using the data from warfarin trial.
win big - win small win small - not win win big - not win
low & adhere 0.095 0.695 0.115
low & not adhere 0.650 0.130 0.575
high & adhere 0.805 0.220 0.750
high & not adhere 0.880 0.210 0.790
The different results from the 3 trials suggest us that such behaviors can be domain specific
and we might not be powered to detect statistically significant patterns across studies yet,
therefore future studies are needed to test the application of this model, or improved version
of such model on a larger group of clinical trials in order to derive definitive evidences.
4.5 Discussion
In this paper, we constructed HMM to model the dynamic effect of financial incentives
towards patient’s tendency to adhere. Previous literature studies the overall financial in-
centive effect after the trial finishes while we studies the dynamic effect at different times,
e.g., given patient’s information on day t, how does the lottery result affect patient’s ten-
dency to adhere on day t+ 1.
We assume that everyday the patient is in a hidden state which determines his tendency(probability)
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to adhere. If the patient does adhere and wins the lottery, he receives a real money incen-
tive. If the patient does not adhere, he will still be informed of the lottery result, if he hears
that he could have won the lottery if he adhered, there is also a regret effect. We assume
these effects directly affect the transition probability of patient’s hidden state.
We fit our model to 3 different trials, which all have a very similar procedure as well as the
lottery system. We interpret the result by dividing patients into four groups, and in each
group compare the probability to adhere in the next day if given different lottery results.
Notice that in real life, the hidden state can not be observed so for one patient at one day,
we can not exactly figure out his group. However, Baum-Welch algorithm provides the
posterior distribution of the hidden state, which could be used as an inference of patient’s
group.
The results we get from the three trials are very different. In warfarin trial there is no
significance at all. In walking trial, we find significance difference for real money incentive
if the patient win big v.s. not win. However, in glucose trial, there is significance for regret
effect if the patient win small v.s. not win. The different results from the 3 trials suggest
us that such behaviors can be domain specific and we might not be powered to detect
statistically significant patterns across studies yet, therefore future studies are needed to
test the application of this model, or improved version of such model on a larger group of
clinical trials in order to derive definitive evidences.
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APPENDIX : Proof for Main Results in Chapter 2
A.1 The distribution of AR statistic and power calculation
Recall the model we constructed is
Y ∗ = βD∗ + δσ1Z∗ + u∗
D∗ = γZ∗ + v∗
Y ∗ = MXY ; D∗ = MXD; Z∗ = MXZ; u∗ = MXu; v∗ = MXv;
(u, v) ⊥ Z; (ui, vi)T ∼ N (0,Σ) ; Σ =
 σ21 ρσ1σ2
ρσ1σ2 σ
2
2
 rank(X) = k
(A.1)
and the AR test statistic is
AR(β0) =
(Y ∗ − β0D∗)TPZ∗(Y ∗ − β0D∗)
(Y ∗ − β0D∗)TMZ∗(Y ∗ − β0D∗)/(n− k − 1) (A.2)
In this section, we will prove the distribution of AR statistic under the alternative hypothesis
H1 : β − β0 = λ in sensitivity analysis:
AR(β0) ∼ F
1,n−k−1, (γ+δ∗σ1/λ)2Z∗T Z∗
σ22
Λ
(A.3)
If the IV is valid, then δ∗ = 0 becomes a specific case for no sensitivity. After (A.3) is
proved, the power formula in original paper can be directly calculated.
Lemma 2. In model (A.1), we have
r(MXPZ∗MX) = 1; r(MXMZ∗MX) = n− k − 1
where r(A) is the rank of matrix A.
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Proof of Lemma 2: Since MX = In−PX is a projection matrix, it is also idempotent, so
Z∗ = MXZ = MXMXZ = MXZ∗
therefore,
MXPZ∗ = MXZ
∗(Z∗TZ∗)−1Z∗T = Z∗(Z∗TZ∗)−1Z∗T = PZ∗ (A.4)
Similarly,
PZ∗MX = Z
∗(Z∗TZ∗)−1Z∗TMX = Z∗(Z∗TZ∗)−1Z∗T = PZ∗ (A.5)
Since Z∗ is a n× 1 vector, by (A.4) and (A.5) we have
r(MXPZ∗MX) = r(PZ∗) = 1 (A.6)
For MXMZ∗MX , it’s equivalent to
MXMZ∗MX = MX(In − PZ∗)MX = MX − PZ∗
From (A.4) and (A.5) we can also get (MX − PZ∗)(MX − PZ∗) = MX − PZ∗ , so MX − PZ∗
is also an idempotent matrix. The result 2.3.9 from Ravishanker and Dey (2001) shows
r(MXMZ∗MX) = tr(MXMZ∗MX) = tr(MX−PZ∗) = tr(MX)− tr(PZ∗) = n−k−1 (A.7)
(A.6) and (A.7) together proved this lemma.
Now we start proving (A.3).
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Proof of (A.3): First, the term Y ∗ − β0D∗ can be transformed as
Y ∗ − β0D∗ = βD∗ + δ∗σ1Z∗ + u∗ − β0D∗
= (λγ + δ∗σ1)Z∗ + λv∗ + u∗
= MXw
where
w = (λγ + δ∗σ1)Z + λv + u ∼ Nn((λγ + δ∗σ1)Z, σ2In)
σ2 = σ21 + 2ρσ1σ2λ+ σ
2
2λ
2
Consider (w/σ)T (MXPZ∗MX)(w/σ) and (w/σ)
T (MXMZ∗MX)(w/σ), by Lemma 2 we know
r(MXPZ∗MX) = 1; r(MXMZ∗MX) = n− k − 1 (A.8)
We also showed
MXPZ∗MX = PZ∗ and MXMZ∗MX = MX − PZ∗ are idempotent matrices (A.9)
We also have
MXPZ∗MX ·MXMZ∗MX = PZ∗(MX − PZ∗) = 0 (A.10)
(A.8)-(A.10) satisfy the conditions stated in result 5.4.8, Ravishanker and Dey (2001).
This result directly leads to the following facts (Notice the different usage of non-central
parameter between Ravishanker and Dey (2001) and this paper. Ravishanker and Dey
(2001) has an extra constant 1/2.)
(w/σ)T (MXPZ∗MX)(w/σ) ∼ χ21
(
(λγ + δ∗σ1)2Z∗TZ∗
σ2
)
(A.11)
(w/σ)T (MXMZ∗MX)(w/σ) ∼ χ2n−k−1 (A.12)
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(w/σ)T (MXPZ∗MX)(w/σ) and (w/σ)
T (MXMZ∗MX)(w/σ) are independent (A.13)
Finally, (A.11)-(A.13) lead to the proof of (A.3):
AR(β0) =
(w/σ)T (MXPZ∗MX)(w/σ)
(w/σ)T (MXMZ∗MX)(w/σ)/(n− k − 1)
∼ F
1,n−k−1, (λγ+δ∗σ1)2Z∗T Z∗
σ21+2ρσ1σ2λ+λ
2σ22
A.2 Power formula in relationship with the non-centrality
parameter
For the power formula
Power0 = 1−Ψ
1,n−k−1, γ2Z∗T Z∗
σ22
Λ
(
F1,n−k−1,∆2Z∗TZ∗;1−α
)
(A.14)
We will prove the following five propositions:
Proposition 3. In the power formula (A.14), we have
(a) If ncp1 = ncp2, the power is always α.
(b) For fixed ncp2, power increases as ncp1 increases.
(c) For fixed ncp1, power decreases as ncp2 increases.
(d) If ncp1 > ncp2, the power is larger than α and will increase to 1 as the sample size
increases.
(e) If ncp1 < ncp2, the power is smaller than α and will decrease to 0 as the sample size
increases.
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We start by proving the following Lemmas:
Lemma 4. Suppose X ∼ N(0, 1), s > 0, t > 0, then
P (X2 < s) > P ((X + t)2 < s)
Proof of Lemma 4: Let fZ(·) be the PDF of standard normal distribution, then
P (X2 < s)− P ((X + t)2 < s) = P (−√s < X < √s)− P (−√s− t < X < √s− t)
= P (
√
s− t < X < √s)− P (−√s− t < X < −√s)
=
∫ t
0
fZ(
√
s− w)dw −
∫ t
0
fZ(−
√
s− w)dw (A.15)
Since ∀s > 0, w > 0, we have (√s− w)2 < (−√s− w)2, therefore
fZ(
√
s− w) = 1√
2pi
exp
(
−(
√
s− w)2
2
)
>
1√
2pi
exp
(
−(−
√
s− w)2
2
)
= fZ(−
√
s− w)
Combining with (A.15), we proved Lemma 4.
P (X2 < s) > P ((X + t)2 < s)
Lemma 5. Suppose Ψa,b,n(x) is the CDF of the non-central F distribution with degree of
freedom a, b and non-centrality parameter n. Then for fixed x0, Ψa,b,n(x0) increases as n
increases.
Proof of Lemma 5: We want to show that ∀ positive n1 < n2, Ψa,b,n1(x0) < Ψa,b,n2(x0).
Let X ∼ N(0, 1), Y ∼ χ2a−1(n1), Z ∼ χ2b . X,Y, Z are independent.
S1 =
X2 + Y
Z
∼ Fa,b,n1 , S2 =
(X +
√
n2 − n1)2 + Y
Z
∼ Fa,b,n2 ,
For fixed x0, define random variable W = Zx0 − Y , suppose fW (w) is the pdf of W .
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Combined with the result from Lemma 4, we have:
Ψa,b,n1(x0) = P (X
2 < W )
=
∫ ∞
t=0
P (X2 <
√
w)fW (w)dw
>
∫ ∞
t=0
P ((X +
√
n2 − n1)2 <
√
w)fW (w)dw
= P (X +
√
n2 − n1)2 < W )
= Ψa,b,n2(x0)
Thus Lemma 5 is proved.
Now we come back to prove Proposition 3. (a) is very straightforward. (b) is equivalent to
Lemma 5, which is proved. For (c), it’s equivalent to prove
Fa,b,n1;1−α < Fa,b,n2;1−α, ∀n1 < n2 (A.16)
We have,
Ψa,b,n1(Fa,b,n1;1−α) = 1− α = Ψa,b,n2(Fa,b,n2;1−α)
By Lemma 5 we also have
Ψa,b,n1(Fa,b,n1;1−α) > Ψa,b,n2(Fa,b,n1;1−α)
Therefore,
Ψa,b,n2(Fa,b,n1;1−α) > Ψa,b,n2(Fa,b,n2;1−α) ⇒ Fa,b,n1;1−α < Fa,b,n2;1−α
Hence A.16 is proved and (c) holds.
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Now we prove (d), as sample size n increases, Z∗TZ ∼ nVar(Z∗), so let ncp1 = an, ncp2 =
bn, a > b > 0 in power formula (A.14). Suppose X1 ∼ N(
√
an, 1), X2 ∼ N(
√
bn, 1),
Y ∼ χ2n−k−1/(n − k − 1), X1, X2, Y are independent, then X21/Y ∼ F1,n−k−1,ncp1 and
X22/Y ∼ F1,n−k−1,ncp2 . Also let q = F1,n−k−1,ncp2;1−α, then in order to prove (d) we just
need to show
lim
n→∞P (X
2
1/Y > q) = 1 (A.17)
First for any  > 0, we have
1− α = P (X22/Y < q)
= P (X22 < qY, Y < 1− ) + P (X22 < qY, Y > 1− )
> 0 + P (X22 < q(1− ), Y > 1− )
= P (X22 < q(1− ))P (Y > 1− )
Since Y
a.s.→ 1, so for fixed  = a−ba+b > 0, ∃N , such that ∀n > N , P (Y > 1 − ) > 1−α1−α/2 .
Also notice X2 ∼ N(
√
bn, 1). Let ψα represents the α-th quantile of standard normal
distribution, then ∀n > N , we have
P (|X2| <
√
q(1− )) < 1− α/2
⇒
√
q(1− )−
√
bn < ψ1−α/4
⇒ √q −
√
n(a+ b)/2 < ψ1−α/4
√
a+ b
2b
(A.18)
Now back to (A.17), for any δ > 0, we have
P (X21/Y > q) > P (X1 >
√
qY )
= P (X1 >
√
qY , Y < 1 + δ) + P (X1 <
√
qY , Y > 1 + δ)
> P (X1 >
√
q(1 + δ)) + 0
= 1−ΨZ(
√
q(1 + δ)−√an)
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where ΨZ(·) is the CDF of standard normal distribution. Choose any δ < a−ba+b , such that
√
(1 + δ)(a+ b)/2−√a < 0 (A.19)
then (A.18) and (A.19) tell us that
lim
n→∞(
√
q(1 + δ)−√an) = lim
n→∞
(√
1 + δ
(
√
q −
√
n
a+ b
2
)
+
(√
(1 + δ)
a+ b
2
−√a
)
√
n
)
< lim
n→∞
(√
1 + δψ1−α/4
√
a+ b
2b
+
(√
(1 + δ)
a+ b
2
−√a
)
√
n
)
= −∞
which directly leads to
lim
n→∞P (X
2
1/Y > q) = 1− limn→∞ΨZ(
√
q(1 + δ)−√an) = 1
Hence property (d) is proved. Similarly we can prove (e) by following a similar procedure.
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